Composition for localized bone formation

A scaffold composed of hydroxyapatite, tricalcium phosphate, and bioactive glass uniformly distributed within, addresses the inconsistency of existing osteogenesis materials by enhancing bone mineralization and growth, particularly in large bone defects.

JP2024542250APending Publication Date: 2024-11-13オシフィ セラピューティクス リミティド ライアビリティ カンパニー

Patent Information

Application Number
JP2024530422
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-23
Filing Date
2022-11-23
Publication Date
2024-11-13

AI Technical Summary

Technical Problem

Current materials for osteogenesis, such as sterile tricalcium phosphate scaffolds with type 1 collagen and bioactive glass, fail to provide consistent and uniform mineral levels in vitro, leading to inadequate bone formation and healing in large bone defects.

Method used

A scaffold comprising hydroxyapatite, tricalcium phosphate, and bioactive glass in specific ratios, with the bioactive glass uniformly distributed throughout, is used to enhance bone formation and healing by promoting osteoblastic mineral deposition.

Benefits of technology

The composition provides enhanced mineralization and bone growth at sites of bone formation, effectively addressing the limitations of existing materials by ensuring consistent and uniform mineral distribution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542250000001_ABST
    Figure 2024542250000001_ABST
Patent Text Reader

Abstract

Provided herein is a composition for bone formation comprising a scaffold, the scaffold being made of hydroxyapatite (HA) and tricalcium phosphate (TCP) in a ratio of 0 / 100 to 15 / 85, collagen, and bioactive glass, the bioactive glass being uniformly dispersed both inside and on the surface of the scaffold, and the composition being sterilized and packaged.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit under 35 USC § 119(e) of U.S. Provisional Patent Application No. 63 / 282,629, filed November 23, 2021, which is incorporated herein by reference in its entirety.

[0002] STATEMENT OF RIGHTS TO INVETIONS MADE UNDER FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT N / A

[0003] REFERENCE TO A "SEQUENCE LISTING," TABLE, OR COMPUTER PROGRAM LISTING APPENDIX SUBMITTED ON A COMPACT DISC N / A [Background technology]

[0004] Bone homeostasis involves the balanced processes of bone formation and bone resorption. Increased bone resorption and loss of bone homeostasis are associated with many diseases and disorders, such as osteoporosis and Paget's disease. All FDA-approved drugs for the treatment of low bone density, except for teriparatide, inhibit bone resorption by stopping it, making them anti-resorptive agents. Anti-resorptive agents act on osteoclasts by stopping them from resorbing bone.

[0005] It is well known in the art that bone can be formed by two processes, one of which is mediated through chondrocyte-cartilage intermediates (endochondral) and the other is a direct process that stimulates osteoblasts (intramembraneous). In the endochondral process, chondrocytes die, creating a void that osteoblasts occupy and mineralize on the surface of the chondrocyte cartilage mineralization. During the resorption process, osteoclasts resorb the cartilage mineralization, leaving clean bone mineral other than cartilage. The endochondral process is present during the basal formation and growth of long bones, as well as during the cartilage callus process of fractures. The endochondral process begins when mesenchymal stem cells differentiate into chondrocytes to form cartilage. On the other hand, the intramembranous process occurs during the growth phase of new bone in fractures and during the formation of the head bone. The intramembranous process occurs when mesenchymal stem cells differentiate into osteoblasts. Unlike cartilage, which is an elastic tissue, bone is hard and rigid. Two very different cellular processes (osteoblasts vs. chondrocytes) involve different molecular mechanisms (WNT vs. BMP) and cellular mechanisms (osteoblasts vs. chondrocytes).

[0006] It is well understood that osteoblasts are involved in the secretion of bone mineral that leads to increased bone density, and to date, only teriparatide is known to stimulate osteoblasts to increase mineral deposition, albeit indirectly via the Wnt pathway.

[0007] It is desirable to induce osteoblast mineral deposition (bone formation) for the successful placement of various medical orthopedic and periodontal implants (e.g., screws, rods, titanium cages or other cages for spinal fixation, hip, knee, ankle, shoulder, dental implants, bone grafts, plates and rods, etc.), as well as for the treatment of a wide variety of different disorders in mammals, including simple aging, bone degeneration and osteoporosis, fracture healing, osteogenesis imperfecta, HPP, fusion of two bones or arthrodesis across a joint, degenerative joint disease, degenerative periodontal disease or periodontitis, any low bone density disorder, etc.

[0008] A current medical need that is not met using currently approved treatments in the field of non-fixed fractures is the desire to improve the poor healing seen in large defects in long bones consisting of large gaps between the fracture ends. The use of demineralized bone or similar osteoconductive materials known in the art has often not provided the desired effect of fixating long bones across small or larger gaps.

[0009] A variety of materials are available to support bone formation, including a sterile tricalcium phosphate (TCP) scaffold with a collagen type 1 (Col1) binder. However, this material provides incomplete or inconsistent mineral levels in vitro. Another system includes a sterile TCP scaffold with a Col1 binder, which also has bioactive glass encapsulated in it. This material also fails to provide complete or consistent mineral levels in vitro. Yet another material available is a two-part sterile system. Component 1 is a TCP scaffold with a Col1 binder. Component 2 is 45S5 bioactive glass (particle size 90-150 microns). Components 1 and 2 must be combined by the surgeon in the operating room, which can result in uneven distribution of the bioactive glass within the scaffold system, leading to variability.

[0010] Thus, there remains a need in the art for new compositions and methods for treating bone disorders, fractures, and related problems. The present invention meets these and other needs. Summary of the Invention

[0011] In view of the shortcomings of materials available for bone formation, provided herein in one aspect is a method for the preparation of a vascular endothelial cell comprising: a) a scaffold comprising hydroxyapatite and tricalcium phosphate in a ratio of 0 / 100 to 15 / 85, collagen, and bioactive glass, the bioactive glass being uniformly dispersed both inside and on the surface of the scaffold; b) Formula I: [ka] [wherein the variables X, Y, Z, A and R 2 has the meaning described below], or a salt, hydrate, prodrug or isomer thereof, which is sterilized and packaged.

[0012] Surprisingly, such compositions provide enhanced mineralization and bone growth at the site of bone formation.

[0013] In another aspect, provided herein is a composition for bone formation comprising a scaffold, the scaffold being a scaffold of hydroxyapatite (HA) and tricalcium phosphate (TCP) in a ratio of 0 / 100 to 15 / 85, collagen, and bioactive glass, the bioactive glass being uniformly dispersed both inside and on the surface of the scaffold, and the composition being sterilized and packaged.

[0014] In yet another aspect, provided herein is a method of promoting bone formation in a subject in need thereof, comprising locally administering to the subject an effective amount of one or more of the compositions described herein. [Brief description of the drawings]

[0015] [Figure 1]FIG. 1 shows that ARS mineralization is decreased in the presence of a 15% HA / 85% TCP scaffold. Column 1 represents wild-type mineralization, where cells have no additive (sclerostin, O20221-1:4-(2-(2-methoxy-8-(trifluoromethyl)-9H-pyrrolo[2,3-b:5,4-c']dipyridin-9-yl)ethyl)morpholine, scaffold). Addition of ectopic sclerostin inhibits normal mineralization (column 3). Positive control O20221-1 in the presence of sclerostin restores normal mineral (compare columns 3 and 5). 15% HA / 85% TCP scaffold alone fails to produce 100% wild-type mineral (compare column 1 with column 2), and fails to restore 100% wild-type mineral in the presence of sclerostin (column 4). O20221-1 loaded with 15% HA / 85% TCP scaffold is unable to restore normal mineralization (column 6 compared to column 1).

[0016] [Diagram 2] Figure 1 shows that ARS mineralization is decreased by increasing 15% HA / 85% TCP scaffold size. Column 1 represents wild type mineralization, cells have no additives (sclerostin, O20221-1, scaffold or granules). In column 2, sclerostin inhibits wild type mineralization. Addition of O20221-1 in the presence of sclerostin restores normal mineral (column 3). Decreasing the size of the scaffold from 0.12cc to 0.01cc restores the decreased mineral (column 7) to wild type mineral levels (dose response and columns 4-7). 15% HA / 85% TCP scaffolds show decreased mineral as the scaffold size is increased from 0.01cc to 0.12cc (compare column 4 to 1).

[0017] [Diagram 3]Figure 1 shows that ARS mineralization is decreased by increasing percentage of HA content. Column 1 represents wild type mineralization, cells have no addition (sclerostin, O20221-1, scaffold or granules). In column 2, sclerostin inhibits wild type mineralization. Addition of O20221-1 in the presence of sclerostin restores normal mineral (column 3). Addition of 15% HA / 85% TCP scaffold alone shows a decrease in wild type mineral (compare column 4 to 1). Increasing concentrations of HA (5-50% percentage) reduces wild type mineral produced (dose response and columns 5-8).

[0018] [Figure 4] Table summarizing unexpected results. The first five columns show the effect of varying HA content from 0-50% on mineralization rates from 100% to 0%. The low mineralization of scaffolds in the presence of sclerostin and O20221-1 can be restored by the addition of non-encapsulated bioactive glass (columns 6 and 7 compared to columns 2 and 3). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] I. Introduction Bone mass homeostasis and bone remodeling involve the balanced processes of bone formation (osteoblast mineral deposition, an anabolic process) and bone resorption (osteoclast mineral resorption, bone loss, a catabolic process). In healthy bone, the two processes are coupled. In bone formation, osteoblasts synthesize bone matrix and regulate mineralization before finally differentiating into osteocytes or bone-lining cells. In bone resorption, a different cell type, osteoclasts, removes the mineralized bone matrix and breaks down organic bone, releasing calcium into serum. See, e.g., Kular et al., Clinical Biochemistry 45:863-873 (2012).

[0020] Osteoblasts (bone-forming cells) and osteoclasts (bone-resorbing cells) are regulated by different mechanisms. Osteoclast differentiation is regulated or controlled by osteoblasts (Glass et al., Dev Cell 8:751-764 (2005)) or other hormones such as PTH, calcitonin, or IL6. In contrast, osteoblast differentiation or activity is not regulated or controlled by osteoclasts, but is controlled by different signals such as CPFA, hedgehog, WNT / LRP, and sclerostin. Bone formation can occur through endochondral ossification or intramembranous ossification (sclerostin). In intramembranous ossification, bone is formed directly by stimulation of osteoblasts / osteocytes. In endochondral ossification, bone formation takes longer because bone formation is through a cartilage template. It has been shown that BMP signaling is involved in endochondral ossification, while Wnt signaling is involved in both endochondral and intramembranous ossification.

[0021] In normal health, bone remodeling (or bone homeostasis) involves the breakdown of old bone (via osteoclasts) and the repair or replacement of old bone with new bone (via osteoblasts). When this homeostasis is disturbed and bone resorption exceeds bone formation, i.e., in pathological bone conditions, bone resorption and bone formation become uncoupled. Increased bone resorption leads to a decrease in bone mass or density (loss of trabecular bone) and weakening of bones (reduced bone strength). Many diseases and conditions are associated with increased bone resorption or reduced bone strength / quality, including osteoporosis, osteogenesis imperfecta, Paget's disease of bone, metabolic bone diseases, bone changes secondary to cancer, and other diseases characterized by or associated with low bone density.

[0022] Diseases caused by increased bone resorption are associated with decreased bone mass density and weakened bones and are often treated with anti-resorptive agents such as bisphosphonates, denosumab, Prolia, alendronate, cathepsin K modulators, RankL inhibitors, estrogen, cathepsin K inhibitors, selective estrogen receptor modulators, and vitamin D, to name just a few. These agents work by directly or indirectly preventing or inhibiting osteoclast bone resorption. However, these agents do not promote new bone formation by osteoblasts (i.e., anabolic bone formation). In contrast, a single dose of an anabolic agent typically increases bone formation in the lumbar spine in humans by more than 8% per year from baseline (Padhi et al. 2010 JBMR). Anti-resorptive agents increase bone mineral density slowly, less than 7% in the first year, but thereafter, bone mineral density increases less than 3.5%, with a cumulative annual increase of less than 10%. Therefore, the weak osteoporotic bones treated with anti-resorptive agents will not become weaker, but will not become stronger or have increased strength, because the anti-resorptive agents will not promote new bone growth by depositing more bone minerals to increase bone density.In contrast, agents that promote anabolic growth of bone will promote the deposition of more bone matrix, for example, by stimulating osteoblast activity, or if proliferation is stimulated, the agent will result in more osteoblasts, which will result in more bone cells filling the gap to hold two bones together.Therefore, the weak osteoporotic bones treated with anabolic bone forming agents will not become weaker, and will have increased bone strength due to increased bone formation.

[0023] Without being bound by any particular theory, if bone is like a bathtub, the drain is like bone loss or resorption, and the faucet is like bone addition or formation. Both the faucet and the drain are added and removed at the same rate (interlocking) until old age or disease causes the faucet to be turned off or the drain to become larger. Such a perturbation causes an imbalance in formation / resorption (segregation) and reduces bone density. For example, imagine a sponge with a core on the outside and fibers stretching from end to end on the inside. During bone resorption, these fibers are removed, but if bone resorption is occurring at a faster rate than bone building or formation, there will be fewer of these fibers and the bone will be weaker. It takes less force to break a sponge with fewer fibers on the inside and a sponge with more fibers on the inside. The process of bone resorption is well understood, and many of the commercially available therapeutics stop bone resorption by acting on osteoclasts. These include anti-resorptive agents such as cathepsin K inhibitors, rank ligand inhibitors, denosumab, Prolia, Fosamax, Evista, Premarin, osteoprotegerin (OPG) inhibitors, alendronate, selective estrogen receptor modulators (SERMs), bisphosphonates, and other agents that act to stop osteoclast activity.

[0024] If we think of bones as a sponge, to increase the strength of bones, we need to increase the number of fibers inside the bone, increase their thickness, and increase their strength, thereby increasing the strength of the bone as a whole. However, we cannot increase the strength of bones by acting on osteoclasts, which are bone-resorbing cells. Therefore, we need to focus on osteoblasts, which form bone. Unlike bone resorption, bone formation is not well understood, and until recently, there was only one systemic treatment (teriparatide) and one surgical implant (injection with BMP protein) available to promote bone formation. However, BMP products act to first increase chondrocytes and promote cartilage production before undergoing endochondral bone formation. This process can also result in chondrocytes being replaced by osteoblasts.

[0025] Intermittent administration of teriparatide increases bone density systemically by activating PKA, which phosphorylates LRP and activates the WNT pathway (Wan et al., Genes Dev. 22(21):2968-2979 (2008)). This increase in bone density occurs along trabeculae already laid down within the bone matrix. Osteoblasts overlying the trabeculae secrete mineral onto the existing trabeculae, increasing the mineral content and density of the trabeculae.

[0026] When a bone void exists, a large portion of the bone is removed or missing, causing a bone non-fixation or critical size defect. The bone is unable to heal naturally across the large gap. Addition of BMP to the site will cause the pluripotent cells to differentiate into chondrocytes / cartilage and generate a cartilage callus. To be able to fill the gap with bone instead of cartilage, it would be necessary for osteoblasts, the bone cells, to proliferate and fill the gap and deposit minerals to fill the void.

[0027] Bioactive glasses are considered as scaffolding materials for bone repair, with the ability to promote bone cell growth and to bond strongly with both hard and soft tissues. Upon implantation, bioactive glasses undergo a specific reaction, resulting in the formation of amorphous calcium phosphate (ACP) or crystalline hydroxyapatite (HA) phases on the surface of the glass, which are responsible for their strong binding with the surrounding tissues. Bioactive glasses have also been reported to release ions that activate the expression of osteogenic genes and stimulate angiogenesis. See Fu, Q., Mater Sci Eng C Mater Biol Appl. 2011 Oct 10; 31(7): 1245-1256.

[0028] Without being bound by any particular theory, the compositions described herein are believed to act as SOST (sclerostin) and / or WISE antagonists that function by modulating the Wnt / LRP and / or BMP signaling pathways. SOST and WISE are proteins that are believed to regulate bone formation by binding to the Wnt co-receptor LRP and inhibiting the Wnt signaling pathway, or by binding to BMP and inhibiting BMP activity, via different amino acid sequences or domains in sclerostin. By neutralizing the inhibitory effect of SOST and / or WISE proteins on the Wnt pathway, the compounds and compositions of the present invention restore Wnt signaling and promote bone formation / growth. Thus, in one aspect, the present invention provides compositions and methods for promoting bone formation in a subject. Bone formation is generally considered to be localized bone formation. The compositions of the present invention can be administered locally, and optionally, sequentially, or in combination with one or more other therapeutic agents. In another aspect, the invention provides an implantable device, such as an orthopedic hardware or a structural scaffold, for migrating osteoblasts / bone cells into the scaffold to deposit bone mineral and for delivering bone forming agents, e.g., to promote bone formation at the implantation site.

[0029] II. Definition As used herein, the term "pharmaceutical acceptable excipient" refers to a substance that aids in the administration and absorption of an active agent by a subject. Pharmaceutically acceptable excipients useful in the present invention include, but are not limited to, binders, fillers, disintegrants, lubricants, coating agents, sweeteners, flavorings, and colorings. Those skilled in the art will recognize that other pharmaceutical excipients are useful in the present invention.

[0030] As used herein, the term "alkyl" refers to a straight or branched chain saturated aliphatic group having the indicated number of carbon atoms. For example, C1C6 alkyl (or C 1~6Alkyl) includes, but is not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, and the like.

[0031] Alkylene refers to a linear or branched alkylene having 1 to 7 carbon atoms, i.e., a divalent hydrocarbon group having 1 to 7 carbon atoms. For example, linear alkylene is represented by the formula (CH2) n [wherein n is 1, 2, 3, 4, 5, 6 or 7]. Preferably, alkylene represents a straight chain alkylene having 1 to 4 carbon atoms, such as a methylene, ethylene, propylene or butylene chain, or a methylene, ethylene, propylene or butylene chain mono-substituted by a C1C3 alkyl (preferably methyl), or a methylene, ethylene, propylene or butylene chain di-substituted on the same or different carbon atoms by a C1C3 alkyl (preferably methyl), the total number of carbon atoms being 7 or less. Those skilled in the art will appreciate that a single carbon of the alkylene is a CH((CH2) n It will be understood that the alkyl group may be divalent, such as CH3), where n=0.5.

[0032] As used herein, the term "alkoxy" or "-O-alkyl" refers to an alkyl containing an oxygen atom, such as methoxy, ethoxy, and the like. "Haloalkoxy" is as defined for alkoxy in which some or all of the hydrogen atoms are replaced with halogen atoms. For example, halo-substituted alkoxy includes trifluoromethoxy, and the like.

[0033] The term "hydroxyalkyl" or "alkyl-OH" refers to an alkyl group as defined above, in which at least one of the hydrogen atoms has been replaced with a hydroxy group. 1~6Exemplary hydroxyalkyl groups include, but are not limited to, hydroxymethyl, hydroxyethyl (when hydroxy is in the 1- or 2-position), hydroxypropyl (when hydroxy is in the 1-, 2-, or 3-position), and the like.

[0034] As used herein, the term "alkenyl" refers to a straight or branched chain hydrocarbon having from 2 to 6 carbon atoms and at least one double bond. Examples of alkenyl groups include, but are not limited to, vinyl, propenyl, isopropenyl, butenyl, isobutenyl, butadienyl, pentenyl, or hexadienyl.

[0035] As used herein, the term "alkynyl" refers to a straight or branched chain hydrocarbon having from 2 to 6 carbon atoms and at least one triple bond. Examples of alkynyl groups include, but are not limited to, acetylenyl, propynyl, or butynyl.

[0036] As used herein, the term "halogen" refers to fluorine, chlorine, bromine and iodine.

[0037] As used herein, the term "haloalkyl" refers to an alkyl as defined above in which some or all of the hydrogen atoms are replaced with halogen atoms. Halogen (halo) preferably represents chloro or fluoro, but may be bromo or iodo. For example, haloalkyl includes trifluoromethyl, fluoromethyl, etc. The term "perfluoro" defines a compound or group having at least two available hydrogens replaced with fluorine. For example, perfluoromethane refers to 1,1,1 trifluoromethyl, and perfluoromethoxy refers to 1,1,1 trifluoromethoxy.

[0038] As used herein, the term "heteroalkyl" refers to an alkyl group having 1-3 heteroatoms, such as N, O, and S. Heteroalkyl groups have the indicated number of carbon atoms with at least one non-terminal carbon replaced with a heteroatom. Additional heteroatoms may also be useful, including, but not limited to, B, Al, Si, and P. Heteroatoms may also be oxidized, such as, but not limited to, S(O) and S(O)2. For example, heteroalkyls may include ethers, thioethers, and alkylamines. Heteroalkyl groups do not include peroxides (-OO-) or other sequentially linked heteroatoms.

[0039] As used herein, the term "oxo" refers to a double-bonded oxygen (=O).

[0040] As used herein, the term "cycloalkyl" refers to a saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring assembly containing 3 to 12 ring atoms, 3 to 8, 3 to 6, or the indicated number of atoms. For example, C 38 Cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and even cyclooctyl. The cycloalkyl groups of this invention are optionally substituted as defined below.

[0041] As used herein, the terms "heterocycle", "heterocycloalkyl", and "heterocyclyl" refer to a ring system having 3 to about 20 ring members and 1 to about 5 heteroatoms, such as N, O, and S. Additional heteroatoms may also be useful, including, but not limited to, B, Al, Si, and P. The heteroatoms may also be oxidized, such as, but not limited to, S(O) and S(O)2. The term heterocycle includes monocyclic, fused bicyclic, and bridged cyclic moieties. For example, heterocycles include, but are not limited to, tetrahydrofuranyl, tetrahydrothiophenyl, morpholino, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, piperidinyl, indolinyl, quinuclidinyl, hexahydro-1H-furo[3,4-c]pyrrolyl, and 1,4 dioxa8azaspiro[4.5]deca8yl. The heterocycloalkyl groups of the present invention are optionally substituted as defined below.

[0042] The substituents on the cycloalkyl and heterocyclyl groups are various and independently include halogen, C 1~8 and wherein R', R'' and R' are independently selected from alkyl, OR', OC(O)R', NR'R'', SR', R', CN, NO2, CO2R', CONR'R'', C(O)R', OC(O)NR'R'', NR''C(O)R', NR''C(O)2R', NR'C(O)NR''R''', S(O)R', S(O)2R', S(O)2NR'R'', perfluoro(C1C4)alkoxy, and perfluoro(C1C4)alkyl, in a number ranging from zero to the total number of open valences on the ring system; and 3~8 heteroalkyl, and phenyl.

[0043] As used herein, a group "linked via a carbon atom" refers to a link between a carbon atom of the referenced group and the remainder of the molecule. A group "linked via a nitrogen atom" refers to a link between the nitrogen atom of the referenced group and the remainder of the molecule. As an example, a heterocyclyl group linked via a carbon atom is [ka] where the wavy line indicates the point of attachment to the rest of the molecule. As an example, a heterocyclyl group linked via a nitrogen atom can be: [ka] where the wavy line indicates the point of attachment to the rest of the molecule.

[0044] As used herein, when a reference is made to a compound that is an N-oxide, it includes a NO bond having three additional bonds to the nitrogen, i.e., an N-oxide is a group R + -O - As an example, an N-oxide is [ka] etc.

[0045] As used herein, the term "aryl" refers to a monocyclic or fused bicyclic, tricyclic or higher aromatic ring assembly containing 6 to 16 ring carbon atoms. For example, aryl can be phenyl, benzyl or naphthyl, preferably phenyl. "Arylene" means a divalent group derived from an aryl group. The aryl group can be mono-, di-, or tri-substituted by one, two, or three groups as described below.

[0046] The substituents on the aryl group are various and include halogen, OR', OC(O)R', NR'R'', SR', R', CN, NO2, CO2R', CONR'R'', C(O)R', OC(O)NR'R'', NR''C(O)R', NR''C(O)2R', NR'C(O)NR''R''', NHC(NH2)=NH, NR'C(NH2)=NH, NHC(NH2)=NR', S(O)R', S(O)2R', S(O)2NR'R'', alkylenedioxy, heteroaryl, -C 1~2 Alkylene-heteroaryl, heterocyclyl, C 1~2 and wherein R', R'' and R''' are selected from alkylene-heterocyclyl, phenyl, perfluoro(C1C4)alkoxy, and perfluoro(C1C4)alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system; and 3~8 Heteroalkyl, and phenyl. Alkylenedioxy is a divalent substituent attached to two adjacent carbon atoms of phenyl, such as methylenedioxy or ethylenedioxy. OxyC2C3 alkylene is also a divalent substituent attached to two adjacent carbon atoms of phenyl, such as oxyethylene or oxypropylene.

[0047] Examples of substituted phenyl groups include, but are not limited to, 4 chlorophenyl, 3,4 dichlorophenyl, 4 methoxyphenyl, 4 methylphenyl, 4 aminomethylphenyl, 4 methoxyethylaminomethylphenyl, 4 hydroxyethylaminomethylphenyl, 4 hydroxyethyl(methyl)aminomethylphenyl, 3 aminomethylphenyl, 4 N-acetylaminomethylphenyl, 4 aminophenyl, 3 aminophenyl, 2 aminophenyl, 4 phenylphenyl, 4(imidazo)phenyl, 4(phenylphenyl), ... Examples of such heteroaryl groups include 4(imidazolylmethyl)phenyl, 4(morpholinyl)phenyl, 4(morpholinylmethyl)phenyl, 4(2-methoxyethylaminomethyl)phenyl, and 4(pyrrolidinylmethyl)phenyl, 4(thiophenyl)phenyl, 4(3-thiophenyl)phenyl, 4(4-methylpiperazinyl)phenyl, and 4(piperidinyl)phenyl and 4(pyridinyl)phenyl, optionally substituted in the heterocyclic or heteroaryl ring.

[0048] As used herein, the term "heteroaryl" refers to a monocyclic or fused bicyclic or tricyclic aromatic ring assembly containing 5 to 16 ring atoms, where 1 to 4 of the ring atoms are heteroatoms, each being N, O or S. For example, heteroaryl includes pyridyl, indolyl, indazolyl, quinoxalinyl, quinolinyl, isoquinolinyl, benzothienyl, benzofuranyl, furanyl, pyrrolyl, thiazolyl, benzothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl, thienyl, or any other group substituted, especially mono- or di-substituted, for example by alkyl, nitro or halogen. Pyridyl represents 2, 3 or 4 pyridyl. Thienyl represents 2 or 3 thienyl. Quinolinyl preferably represents 2, 3 or 4 quinolinyl. Isoquinolinyl preferably represents 1, 3 or 4 isoquinolinyl. Benzopyranyl, benzothiopyranyl preferably represent 3-benzopyranyl or 3-benzothiopyranyl, respectively. Thiazolyl preferably represents 2 or 4-thiazolyl, most preferably 4-thiazolyl. Triazolyl is preferably 1, 2 or 5 (1,2,4-triazolyl). Tetrazolyl is preferably 5-tetrazolyl. The heteroaryl moiety may be optionally substituted as defined below.

[0049] Preferably, heteroaryl is pyridyl, indolyl, quinolinyl, pyrrolyl, thiazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl, thienyl, furanyl, benzothiazolyl, benzofuranyl, isoquinolinyl, benzothienyl, oxazolyl, indazolyl, or any of the substituted, especially mono- or di-substituted, groups.

[0050] Substituents for the heteroaryl group are varied and selected from halogen, OR', OC(O)R', NR'R'', SR', R', CN, NO2, CO2R', CONR'R'', C(O)R', OC(O)NR'R'', NR''C(O)R', NR''C(O)2R', NR'C(O)NR''R''', NHC(NH2)=NH, NR'C(NH2)=NH, NHC(NH2)=NR', S(O)R', S(O)2R', S(O)2NR'R'', N3, CH(Ph)2, perfluoro(C1C4)alkoxy, and perfluoro(C1C4)alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R', R'' and R''' are selected from hydrogen, (C1C8)alkyl and C1C8)alkyl. 3~8 heteroalkyl, and phenyl.

[0051] As used herein, the terms "ring member" and "ring vertex" are intended to have the same meaning. For example, a six-membered ring has six ring vertices.

[0052] As used herein, the term "salt" refers to the acid salt or base salt of the compound used in the method of the present invention. Examples of pharmaceutically acceptable salts are mineral acid (hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, etc.) salts, organic acid (acetic acid, propionic acid, glutamic acid, citric acid, etc.) salts, and quaternary ammonium (methyl iodide, ethyl iodide, etc.) salts. It is understood that pharmaceutically acceptable salts are non-toxic. Additional information regarding suitable pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, which is incorporated herein by reference.

[0053] Pharmaceutically acceptable salts of the acidic compounds of the invention are salts formed with bases, i.e., cationic salts such as alkali metal salts and alkaline earth metal salts, such as sodium, lithium, potassium, calcium, magnesium, and the like, as well as ammonium salts, such as ammonium, trimethylammonium, diethylammonium, and tris(hydroxymethyl)methylammonium salts.

[0054] Likewise possible are acid addition salts of mineral acids, organic carboxylic acids and organic sulfonic acids, such as hydrochloric acid, methanesulfonic acid, maleic acid and the like, provided that a basic group, such as pyridyl, forms part of the structure.

[0055] The neutral forms of the compounds can be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for purposes of the invention.

[0056] As used herein, the term "bioactive glass" or "bioglass" refers to silica composites useful for bone grafts, periodontal defect repair, and cranial and maxillofacial restorations. A common bioactive glass is Bioglass 45S5 or calcium sodium phosphosilicate, specifically a bioactive glass composed of 45% SiO2, 24.5% CaO, 24.5% Na2O, and 6.0% PO5 by weight, commercially available as NovaMin. Other bioactive glass compositions include: S53P4: 53 wt% SiO2, 23 wt% Na2O, 20 wt% CaO, and 4 wt% P2O5; 58S: 58 wt% SiO2, 33 wt% CaO, and 9 wt% P2O5; 70S30C: 70 wt% SiO2, 30 wt% CaO; 13-93: 53 wt% SiO2, 6 wt% Na2O, 12 wt% K2O, 5 wt% MgO, 20 wt% CaO, and 4 wt% P2O5.

[0057] As used herein, the term "calcium salt" refers to a salt containing calcium. Examples of calcium salts include calcium acetate, calcium aluminate, calcium aluminosilicate, calcium arsenate, calcium borate, calcium bromide, calcium carbide, calcium carbonate, calcium chlorate, calcium chloride, calcium citrate, calcium citrate malate, calcium cyanamide, calcium dihydrogen phosphate, calcium fluoride, calcium formate, calcium glubionate, calcium glucoheptonate, calcium gluconate, calcium glyceryl phosphate, calcium hexaboride, calcium hydride, calcium hydroxide, calcium hypochlorite, calcium inosinate, calcium iodate, calcium iodide, calcium lactate, Examples of suitable calcium salts include, but are not limited to, calcium lactate gluconate, calcium acetate magnesium, calcium malate, calcium nitrate, calcium nitride, calcium oxalate, calcium oxide, calcium pangamate, calcium peroxide, calcium phosphate, calcium phosphide, calcium propionate, calcium pyrophosphate, calcium silicate, calcium silicide, calcium sorbate, calcium stearate, calcium sulfate, calcium sulfide, calcium tartrate, calcium (I) chloride, dicalcium citrate, dicalcium phosphate, dodecacalcium heptaaluminate, tricalcium aluminate, tricalcium phosphate, and triple superphosphate. Those skilled in the art will appreciate that other calcium salts are useful in the present invention.

[0058] As used herein, the term "hydrate" refers to a compound that is complexed with at least one water molecule. The compounds of the present invention can be complexed with 1 to 10 water molecules. The term "hydrate" also includes hemihydrates, in which there are two compounds for every water molecule in the complex.

[0059] Certain compounds used in the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are all intended to be embraced within the scope of the present invention.

[0060] As used herein, the term "subject" refers to animals such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, etc. In certain embodiments, the subject is a human.

[0061] As used herein, the terms "therapeutically effective amount" or "therapeutically sufficient amount" or "effective or sufficient amount" refer to the amount administered that produces a therapeutic effect. The exact amount will depend on the purpose of the treatment and will be ascertainable by one of ordinary skill in the art using known techniques.

[0062] As used herein, the term "site of injury or localized condition" refers to a specific location in the body of a subject in need of treatment by the methods of the present invention. For example, the injury can be a bone fracture and the localized condition can be a disease condition (such as osteoporosis) that is limited to a specific location in the subject's body, such as a specific bone, joint, finger, hand, foot, limb, spine, head, torso, etc. In some embodiments, the site of injury or localized condition is a surgical implant site.

[0063] As used herein, the term "promoting bone formation" refers to stimulating new bone formation, growing bone across a joint or gap, enhancing or promoting bone formation, and / or increasing bone density or bone mineral content. In some embodiments, a compound promotes bone formation if it increases the amount of bone in a sample by at least 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, or more relative to a control sample (e.g., a sample not contacted with the compound).

[0064] As used herein, the term "arthrodesis" refers to the artificial induction of joint ossification between two bones and / or across a joint, often performed by surgery. Arthrodesis can be accomplished by the use of bone grafts, metal implants, or synthetic bone substitutes, among others.

[0065] As used herein, the term "bone autograft" refers to transplanting a subject's own bone.

[0066] As used herein, the term "bone allograft" refers to the transplantation of bone from one person to another.

[0067] As used herein, the term "antiresorptive drug" refers to drugs that slow or block bone resorption and / or that act on osteoclasts.

[0068] As used herein, the term "bone-related disease characterized by low bone mass" refers to a bone T-score of less than 0.5. Other methods of determining low bone mass are known to those skilled in the art.

[0069] As used herein, the term "fracture" refers to a crack, break, or fracture of a bone at one or several locations along the bone. In some embodiments, the term "fracture" also includes the absence of a connected segment.

[0070] As used herein, the term "spinal fusion" refers to a surgical technique for combining or fusing two or more vertebrae.

[0071] As used herein, the term "scaffold" refers to a segment of a device (implantable portion) that can be implanted into a subject. Scaffolds can be prepared from a variety of different materials, as described herein, and further include metals, ceramics, polymers, and inorganic materials, as described below. Non-limiting examples of scaffolds include blocks, cubes, spheres, putties, liquid cements, strips, and granules. The scaffolds can be coated with various materials that promote bone growth. In some embodiments, the entire device comprises an implantable scaffold. For example, in some embodiments, the entire device described herein can be implanted into a surgical site, and the surgical site can be closed over the device.

[0072] As used herein, the term "external coating" refers to a coating of a structural support that may cover only a portion of the structural support (a partial external coating) or that may cover the entire structural support. For example, a partial external coating may completely cover only the embeddable portion of the structural support.

[0073] As used herein, the terms "weakened bones," "low bone density," or "low bone mass" refer to bone mass below 0.5 (0.9 g / cm 2 This refers to bones with a T-score of less than 0.05.

[0074] As used herein, the term "demineralized bone" refers to bone from which inorganic minerals have been removed. The remaining organic collagen material may contain osteoinductive growth factors. These growth factors include osteogenic proteins that induce cartilage and then ossify via endochondral ossification resulting in new bone formation. Demineralized bone often takes the form of "demineralized bone matrix (DBM)". DBM can be made by fresh frozen or freeze-dried bulk bone allografts, or by mild acid extraction of cadaveric bone, which removes the mineral phase leaving behind collagen, growth factors, and non-collagenous proteins that provide the unique properties of osteoconduction. DBM can also be processed in a variety of ways, eventually resulting in a powder that is mixed with a carrier to provide optimal handling characteristics desired by the surgeon. DBM is clinically available as gels, pastes, putties, and fabrics tailored to meet the needs of the surgical procedure. Some DBM is also mixed with antibiotics prior to the surgical procedure.

[0075] As used herein, the term "diabetes" refers to a condition primarily characterized by the body's inability to produce sufficient amounts of insulin, a hormone produced by the pancreas. When released into the bloodstream, insulin induces cellular glucose uptake. Thus, insufficient amounts of insulin lead to elevated blood glucose levels in affected individuals. Those skilled in the art will recognize that the body's inability to produce sufficient amounts of insulin can be a feature of both type 1 and type 2 diabetes.

[0076] As used herein, the term "osteoconductive matrix" refers to a material that can act as an osteoconductive substrate (i.e., allows bone growth) and has a scaffold structure, onto which infiltrating cells can attach, grow, and participate in the process of producing osteoid, the organic phase of bone, ultimately leading to osteogenesis, i.e., the formation of new bone. The terms "matrix" and "scaffold" interchangeably refer to a structural component or substrate that essentially has a three-dimensional form on which certain cellular events involved in bone formation occur. Osteoconductive matrices allow the ingrowth of host capillaries, perivascular tissue, and osteoprogenitor cells. In some embodiments, the osteoconductive matrix includes an "osteoinductive agent" to provide osteogenic potential. An osteoinductive agent, as used herein, is an agent that stimulates the host to proliferate bone cells, thereby producing more bone osteoid.

[0077] As used herein, the terms "treat", "treating" and "treatment" refer to any indication of success in treating or ameliorating an injury, condition, state or symptom (e.g., pain), including any objective or subjective parameter, such as relief; remission; reducing the symptoms or making the symptom, injury, condition or condition more tolerable to the patient; reducing the frequency or duration of the symptom or condition; or, in some circumstances, preventing the onset of the symptom or condition. Treatment or amelioration of symptoms can be based on objective or subjective parameters, such as the results of a physical exam.

[0078] As used herein, the term "RankL inhibitor" refers to a compound or agent that inhibits the activity of RankL. RankL (receptor activator of nuclear factor κB ligand) is important in bone metabolism by activating osteoclasts. RankL inhibitors include, but are not limited to, the human monoclonal antibody denosumab. Those skilled in the art will appreciate that other RankL inhibitors are useful in the present invention.

[0079] As used herein, the term "parathyroid hormone" or "PTH" refers to a compound or drug that acts on PTH receptor to activate pathway.PTH is important in bone metabolism by activating osteoblasts.PTH includes, but is not limited to, teriparatide, forteo, and abaloparatide-SC.Those skilled in the art will understand that other PTHs are useful in the present invention.

[0080] As used herein, the term "combination therapy" refers to the co-administration of a compound of the present invention together, or sequentially, prior to or following administration of a compound of the present invention.

[0081] As used herein, certain compounds have asymmetric carbon atoms (optical centers) or double bonds. Racemates, diastereomers, geometric isomers, positional isomers and individual isomers (e.g., separate enantiomers) are all intended to be encompassed within the scope of the present invention. In some embodiments, the compounds of the present invention are specific enantiomers or diastereomers that are substantially free of other forms. The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may contain, for example, deuterium ( 2 H), tritium ( 3 H), iodine-125( 125 I), or carbon-14 ( 14 C) or non-radioactive isotopes. All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.

[0082] III. Composition In some embodiments, the present invention comprises: a) a scaffold comprising hydroxyapatite and tricalcium phosphate in a ratio of 0 / 100 to 15 / 85, collagen, and bioactive glass, the bioactive glass being uniformly dispersed both inside and on the surface of the scaffold; b) Formula I: [ka] [In the formula, X is CR 3b and N, where N is optionally oxidized to the corresponding N-oxide; Y is CR 3c and N, where N is optionally oxidized to the corresponding N-oxide; Z is CR 3d and N, where N is optionally oxidized to the corresponding N-oxide; With the proviso that at least one of X, Y and Z is N or the corresponding N-oxide; A is, [ka] and; R N is selected from the group consisting of heterocyclyl and heteroaryl; The heterocyclyl moieties are selected from monocyclic, fused bicyclic, and bridged bicyclic, where the monocyclic heterocyclyl contains 4 to 7 ring members and the fused bicyclic and bridged bicyclic heterocyclyl contains 7 to 10 ring members, each heterocyclyl moiety having 1 to 3 heteroatoms as ring members selected from N, O, and S, each heterocyclyl moiety containing at least one nitrogen atom as a ring member and 1 to 3 R 6 is optionally substituted with a moiety, The heteroaryl moiety contains 5 to 10 ring members, at least one ring member being a nitrogen atom, and 1 to 3 R 6 is optionally substituted with a moiety, Each R 2 , R 3b , R 3c and R 3d H, halogen, C 16 Alkyl, C 16 Haloalkyl, C 26 Alkenyl, C 26 Alkynyl, C 16 Alkoxy, C 16 Haloalkoxy, C 16 Alkyl-OH, -OC 16Alkyl-OH, C 36 Cycloalkyl-C 14 independently selected from the group consisting of alkoxy, and -OH; R 6 -OH, C 1~3 Alkyl, C 13 AlkylOH, -OC 1~3 Alkyl, C 3~4 Heteroalkyl, C 1~3 Haloalkyl, -OC 1~3 or a salt, hydrate, prodrug, or isomer thereof; A sterile composition for bone formation is provided that is sterilized and packaged.

[0083] In some embodiments, the compound used in the sterile composition has formula Ia: [ka] wherein each variable position is as defined in Formula I.

[0084] In some embodiments, the compound used in the sterile composition has formula Ib: [ka] wherein each variable position is as defined in Formula I.

[0085] In some embodiments, the compound used in the sterile composition has formula Ic: [ka] wherein each variable position is as defined in Formula I.

[0086] In some embodiments, the compound used in the sterile composition has formula Id: [ka] wherein each variable position is as defined in Formula I.

[0087] In some embodiments, each R in formula I, Ia, Ib, Ic, or Id 2 is a halogen, C 16 Alkyl, C 16 Haloalkyl and C 16 In some embodiments, R in formula I, Ia, Ib, Ic, or Id is independently selected from the group consisting of alkoxy. 2 is C 1~6 Alkyl or C 16 In some embodiments, R in formula I, Ia, Ib, Ic, or Id is haloalkyl. 2 In some embodiments, R in formula I, Ia, Ib, Ic, or Id is 2 is CF3.

[0088] In some embodiments, when present in formula I, Ia, Ib, Ic, or Id, each R 3b , R 3c and R 3d H, halogen, C 16 Alkyl, C 16 Haloalkyl, C 16 Alkoxy, C 16 In some embodiments, when present in formula I, Ia, Ib, Ic, or Id, each R 3b , R 3c and R 3d H, halogens, and C 16 In some embodiments, when present in formula I, Ia, Ib, Ic, or Id, each R 3b , R 3c and R 3d is H, F, and methoxy. In some embodiments, when present in formula I, Ia, Ib, Ic, or Id, R 3b , R 3c and R 3d At least one of R when present in formula I, Ia, Ib, Ic, or Id is F.3b , R 3c and R 3d In some embodiments, when present in formula I, Ia, Ib, Ic, or Id, at least one of R 3b , R 3c and R 3d At least one of them is F and R 3b , R 3c and R 3d At least one of them is methoxy.

[0089] In some embodiments, R of formula I, Ia, Ib, Ic, or Id N In some embodiments, the heteroaryl moiety contains 4 to 8 ring members, at least one ring member is a nitrogen atom, and 1 to 3 R 6 The moiety is optionally substituted.

[0090] In some embodiments, R of formula I, Ia, Ib, Ic, or Id N is a monocyclic heterocyclyl.

[0091] In some embodiments, R in formula I, Ia, Ib, Ic, or Id N teeth, [ka] It is.

[0092] In some embodiments, R in formula I, Ia, Ib, Ic, or Id 6 -OH, C 1~3 Alkyl, C 1~3 Alkyl-OH, -OC 1~3 Alkyl, C 1~3 Haloalkyl, -OC 1~3 In some embodiments, R in formula I, Ia, Ib, Ic, or Id is selected from the group consisting of haloalkyl, halogen, and oxo. 6 is C 1~3 Alkyl, -OC 1~3 Alkyl, C 1~3Haloalkyl, -OC 1~3 In some embodiments, R is selected from the group consisting of haloalkyl, and halogen. 5 -OH, C 1~3 Alkyl or -OC 1~3 It is an alkyl.

[0093] In one group of embodiments, the compound of formula I is [ka] The structure is selected from:

[0094] In some embodiments, the compositions described herein include a formate salt of a compound according to any of the above compounds. In some embodiments, the compositions described herein include a citrate salt of a compound according to any of the above compounds. In some embodiments, the compositions described herein include a hydrochloride salt of a compound according to any of the above compounds.

[0095] The compositions of the invention may also include hydrates, solvates and prodrug forms of the above compounds (as well as other bone forming agents, see, for example, WO 2020 / 037001, WO 2020 / 037004 and WO 2014 / 153203).

[0096] As mentioned above, the compound of formula I used herein can be in salt form.Salt includes but is not limited to sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, phosphonate, isonicotinate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate, i.e., 1,1'methylenebis(2-hydroxy-3-naphthoate)) salt. Other salts include, but are not limited to, salts with inorganic bases, including alkali metal salts such as sodium salts, potassium salts, alkaline earth metal salts such as calcium salts, magnesium salts, aluminum salts, and ammonium salts.Other salts with organic bases include salts with diethylamine, diethanolamine, meglumine, and N,N'dibenzylethylenediamine.In some embodiments, the invention provides a hydrochloride salt.

[0097] In some embodiments, the compounds of formula I used herein contain a nitrogen atom that is optionally further oxidized, i.e., the compounds are N-oxides. As an example, the nitrogen atom in the pyrido-indolyl ring system in the compounds of formula I, Ia, Ib, Ic, or Id is oxidized to the corresponding N-oxide.

[0098] In some embodiments, the compounds of formula I used herein are delivered and / or formulated as prodrugs. In one embodiment, any compound described herein is an ester prodrug. In another embodiment, any compound described herein is an amide prodrug. In a further embodiment, the prodrug moiety comprises a conjugate group that allows selective targeting in bone structures. Examples of such motifs are described in Erez et al., Bioorg.Med.Chem.Lett. 2008,18,816-820 and Neale et al., Bioorg.Med.Chem.Lett. 2009,19,680-683, which are incorporated herein by reference. Thus, estradiol conjugates and / or bisphosphonate conjugates of compounds of formula I are contemplated within the scope of the embodiments presented herein.

[0099] Returning to the scaffold portion of the composition, the scaffold comprises hydroxyapatite and tricalcium phosphate in a ratio of 0 / 100 to 15 / 85, collagen, and bioactive glass, the bioactive glass being uniformly dispersed both inside and on the surface of the scaffold. The scaffold is designed to reliably and reproducibly induce bone formation in the mammalian body, and preferably comprises particles of porous materials (including HA, TCP, collagen, and bioactive glass). The scaffold may have pores, the pores preferably being of a size that allows migration of progenitor cells into the matrix and subsequent differentiation and proliferation. In some embodiments, the pore size of the scaffold is at least 5 μm, e.g., at least 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, 250, 300, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1200, 1500, 1700, or 2000 μm. The scaffold can be made by densely packing the material, molding it to a shape that spans the bone defect, or otherwise structuring a material that is biocompatible and preferably biodegradable or resorbable in vivo, as desired, and serves as a "temporary scaffold" and substratum for the recruitment of migratory progenitor cells and their subsequent colonization and proliferation. In some embodiments, the scaffold comprises a mesh structure, a foam structure, a sponge structure, or a fiber structure.

[0100] As described above, the scaffold comprises hydroxyapatite and tricalcium phosphate in a ratio of 0% hydroxyapatite / 100% tricalcium phosphate (0 / 100) to 15% hydroxyapatite (HA) / 85% tricalcium phosphate (TCP) (15 / 85). In some embodiments, the ratio of HA to TCP is 0 / 100, 1 / 99, 2 / 98, 3 / 97, 4 / 96, 5 / 95, 6 / 94, 7 / 93, 8 / 92, 9 / 91, 10 / 90, 11 / 89, 12 / 88, 13 / 87, 14 / 86, or 15 / 85. In some embodiments, the ratio of HA to TCP is 0 / 100. In some embodiments, the ratio of HA to TCP is 1 / 99. In some embodiments, the ratio of HA to TCP is 2 / 98. In some embodiments, the ratio of HA to TCP is 3 / 97. In some embodiments, the ratio of HA to TCP is 4 / 96. In some embodiments, the ratio of HA to TCP is 5 / 95.

[0101] Suitable densities can be 0.30-1.0 g / cc of scaffold, or 0.4-0.8 g / cc of scaffold, hi some embodiments, the final scaffold density is about 0.5-0.7 g / cc of scaffold.

[0102] The amount of HA / TCP present in the composition may vary, but generally is present in the scaffold composition in an amount of 200 mg to 1000 mg per cc of scaffold. In some embodiments, the amount of HA / TCP present in the scaffold composition is 250 mg to 750 mg per cc of scaffold. In some embodiments, the amount of HA / TCP present in the scaffold composition is 300 mg to 700 mg per cc of scaffold. In some embodiments, the amount of HA / TCP present in the scaffold composition is 320 mg to 650 mg per cc of scaffold. In yet other embodiments, the amount of HA / TCP present in the scaffold composition is 318 mg to 636 mg per cc of scaffold. In some embodiments, the amount of HA / TCP present in the scaffold composition is about 323 mg per cc of scaffold.

[0103] Collagen is another component of the present composition and can be obtained from a variety of commercial sources. Generally, collagen 1 binders are useful in the present composition. In some embodiments, the collagen is crosslinked. In some embodiments, the collagen is crosslinked prior to the addition of the bioactive glass. Type I collagen is the most abundant collagen in the human body and forms large eosinophilic fibers known as collagen fibers. It is present in various tissues, tendons, ligaments, endomysium of myofibrils, and the organic portion of bone, among others. The amount of collagen present in the composition can vary, but generally, it is present in the scaffold composition in an amount of 0-50 mg per cc of scaffold. In some embodiments, the amount of collagen present in the scaffold composition is 7-34 mg per cc of scaffold. In some embodiments, the amount of collagen present in the scaffold composition is about 12 mg to 22 mg per cc of scaffold. In some embodiments, the amount of collagen present in the scaffold composition is about 22 mg per cc of scaffold.

[0104] Bioactive glass is yet another component of the present composition and is also available from a variety of commercial sources. Bioactive glass having a particle size of about 50 to about 500 microns can be used. In some embodiments, the bioactive glass has a particle size of 50 to 200 microns, 75 to 150 microns, 100 to 300 microns, or 90 to 250 microns. The amount of bioactive glass in the present composition can vary, but is generally present in the scaffold composition in an amount of 20 to 300 mg per cc of scaffold. In some embodiments, the amount of bioactive glass is present in the scaffold composition in an amount of 20 to 200 mg per cc of scaffold. In some embodiments, the amount of bioactive glass is present in the scaffold composition in an amount of 75 to 150 mg per cc of scaffold. In some embodiments, the amount of bioactive glass is present in the scaffold composition in an amount of about 125 mg per cc of scaffold.

[0105] Bioglass 45S5 or calcium sodium phosphosilicate, specifically, is a bioactive glass composed of 43-47 wt% SiO2, 22.5-26.5 wt% CaO, 22.5-26.5 wt% Na2O, and 5-7 wt% P2O5.

[0106] Other bioactive glasses include: S53P4: 53% SiO2, 23% Na2O, 20% CaO, and 4% P2O5 by weight; 58S: 58% SiO2, 33% CaO, and 9% P2O5 by weight; 70S30C: 70% SiO2, 30% CaO by weight; 13-93: 53% SiO2, 6% Na2O, 12% K2O, 5% MgO, 20% CaO, and 4% P2O5 by weight. Generally, bioactive glasses have compositions within the following weight percentage ranges: 43-70% SiO2, 20-30% CaO, 0-26.5% Na2O, 0-9% P2O5, 0-12% K2O, and 0-5% MgO.

[0107] The compound of formula I can be added to the scaffold as a pure solid form or in solution (e.g., saline or water, then the compound is allowed to crystallize within and on the scaffold). The compound crystals can be, but are not limited to, amorphous, cubic, or needle-like crystals. Dissolution of the compound crystals in cell culture or biological fluids occurs slowly over time, providing a slow and consistent release of the compound capable of inhibiting sclerostin into the solution or surrounding bone tissue. The compound crystals are generated by placing the solid compound into water or saline with agitation (i.e., sonication) to obtain, for example, a 1.8 mM solution. For each cc of scaffold + bioactive glass, 10-2000 μL of 1.8 mM bone forming agent (API) is added and allowed to diffuse onto and throughout the scaffold or device material. The compound is then allowed to crystallize within the scaffold for 24 hours or more (depending on the overall size and thickness of the scaffold material) and dried. Alternatively, the compound crystals can form independently and do not require a scaffold material to form.

[0108] The scaffold portion of the composition may further comprise a synthetic material, a biological material, or a combination thereof. In some embodiments, the scaffold or matrix comprises a naturally occurring polymer, a synthetic biodegradable polymer, a synthetic non-biodegradable polymer, a bioceramic, a bioactive glass, or a combination thereof. Natural and synthetic polymers, bioceramics, and bioactive glasses for use in scaffolds are known in the art. See, for example, Dhandayuthapani et al., International Journal of Polymer Science, Vol. 2011, Article ID 290602 (2011), which is incorporated herein by reference. Natural polymers include, but are not limited to, proteins (e.g., silk, collagen, gelatin, fibrinogen, elastin, keratin, actin, and myosin), polysaccharides (e.g., cellulose, amylose, dextran, chitin, chitosan, and glycosaminoglycans), and polynucleotides (e.g., DNA and RNA). Synthetic polymers include, but are not limited to, PLA, PGA, PLLA, PLGA, PCL, PLDLA, PDS, PGCL, PEA, PCA, PDLLA, PEU, and PBT. Bioceramics and bioactive glasses include, but are not limited to, HAP, TCP, CP ceramic, BCP, and TCP. In some embodiments, the scaffold or matrix is ​​a hydrogel scaffold, a fibrous scaffold, a microsphere scaffold, a polymer-bioceramic composite scaffold, or an acellular scaffold.

[0109] In some embodiments, the scaffold or matrix is ​​an osteoconductive matrix. Non-limiting examples of suitable additional osteoconductive matrix materials include, for example, homopolymers or copolymers of glycolic acid, lactic acid, and butyric acid (including their derivatives); as well as ceramics, biphasic calcium phosphate and other calcium phosphates, and calcium sulfate, or combinations thereof. Typically, the osteoconductive matrix contemplated herein includes at least one of the materials listed above. Other additional matrix / scaffold components useful in the compositions of the present invention include, but are not limited to, biocomposite bone graft, Kryptonite bone cement (Doctors Research Group, Oxford, CT), Vitoss, Vitoss BA, Orthoblend, Grafton, Arthrex, Allograft, Cadaverbone, Ostoset, Novabone, Augmatrix, Mastergraft, Hydroset, Pro-dense, Pro-stim, hydroset, (porous) tantalum bone graft, titanium mesh, titanium bone graft, and Genex bone graft. Combinations of these matrix materials may also be useful. Osteoconductive matrix components may also include calcium salts, calcium sulfate, calcium phosphate, calcium phosphate cement, dicalcium phosphate, calcium carbonate, collagen, plaster of Paris, phosphophoryn, borosilicate, biocompatible ceramics, calcium phosphate ceramics, polytetrafluoroethylene, sulfates, homopolymers or copolymers of glycolic acid, lactic acid, and butyric acid (including derivatives thereof); as well as additional structural supports such as ceramics, biphasic calcium phosphate and other calcium phosphates, and calcium sulfate.

[0110] In some embodiments, the osteoconductive matrix comprises an osteoinductive agent and, optionally, a structural support. The osteoinductive agent can be any agent that promotes bone formation. In some embodiments, the osteoinductive agent is a bone allograft, a bone autograft, a bone marrow aspirate, demineralized bone, or periodontal ligament cells.

[0111] A variety of sterilization techniques can be used to prepare the final composition prior to packaging, including but not limited to gamma irradiation, electron beam irradiation, UV irradiation, steam heating, dry heat, plasma, EtO, PAA, ethanol, and / or iodine.

[0112] In another aspect, provided herein is a composition for bone formation comprising a scaffold, the scaffold being a scaffold of hydroxyapatite (HA) and tricalcium phosphate (TCP) in a ratio of 0 / 100 to 15 / 85, collagen, and bioactive glass, the bioactive glass being uniformly dispersed both inside and on the surface of the scaffold, and the composition being sterilized and packaged.

[0113] Similar to the related sterile compositions above, this group of compositions draws on structural (and non-structural) scaffolds prepared from combinations of hydroxyapatite (HA), tricalcium phosphate (TCP), collagen, and bioactive glass. In some embodiments, the ratio of HA to TCP is 0 / 100, 1 / 99, 2 / 98, 3 / 97, 4 / 96, 5 / 95, 6 / 94, 7 / 93, 8 / 92, 9 / 91, 10 / 90, 11 / 89, 12 / 88, 13 / 87, 14 / 86, or 15 / 85.

[0114] Generally, compositions can be prepared using commercially available sources of HA and TCP with the addition of collagen (available from a variety of sources). Bioactive glass can then be added to the HA / TCP / collagen scaffold by a variety of techniques to ensure uniform distribution of the bioactive glass both within and on the surface portion of the scaffold.

[0115] For any of the compositions described herein, the sterile product may be in a moldable form, a structurally rigid form, or in the form of a putty or liquid cement.

[0116] A. Additional Bone Forming Agents For any of the above embodiments, additional bone forming agents can be used in place of or in addition to the compounds of formula (I). Additionally, any of the bone forming agents described herein can be added to the compositions of embodiment 2 (below).

[0117] Suitable bone forming agents are described, for example, in WO 2020 / 037001, WO 2020 / 037004, and WO 2014 / 153203.

[0118] In some embodiments, the bone forming agent has the formula: [ka] [In the formula, W is for CR 3a and N, where N is optionally oxidized to the corresponding N-oxide; X is CR 3b and N, where N is optionally oxidized to the corresponding N-oxide; Y is CR 3c and N, where N is optionally oxidized to the corresponding N-oxide; Z is CR 3d and N, where N is optionally oxidized to the corresponding N-oxide; R N is NR 6 R 7 , heterocyclyl, and heteroaryl, where heterocyclyl and heteroaryl contain from about 5 to about 10 ring atoms, at least one of which is nitrogen; R N any N in is optionally oxidized to the corresponding N-oxide; Each R 1a , R 1b , and R 1c is independently selected from H, methyl, and ethyl; 1a )2[C(R 1b )2] q [C(R 1c )2] tThe total number of carbon atoms in does not exceed 6; Each R 2 , R 3a , R 3b , R 3c and R 3d H, halogen, C 16 Alkyl, C 16 Haloalkyl, C 26 Alkenyl, C 26 Alkynyl, C 16 Alkoxy, C 16 Haloalkoxy, aryloxy, C 16 Alkyl OH, OR 4 , C 06 Alkyl NR 4 R 5 , S.R. 4 , C(O)R 4 , C 06 AlkylC(O)OR 4 , C(O)NR 4 R 5 , N(R 4 )C(O)R 5 , N(R 4 )C(O)OR 5 , N(R 4 )C(O)NR 4 R 5 , OP(O)(OR 4 )2, S(O)2OR 4 , S(O)NR 4 R 5 independently selected from the group consisting of CN, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; Alternatively, two R on adjacent atoms 2 Groups can be combined with the atom to which they are attached to form a member selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; Each R 4 , R 5 , R 6 , and R 7 , H, C 16 Alkyl, and C 16 independently selected from the group consisting of alkylOH; The subscript q is an integer from 0 to 4; The subscript t is an integer from 0 to 4; With the proviso that only one of W, X, Y, and Z is N or the corresponding N-oxide; however, a) The sum of q and t is 1, and b) If present, R 6 or R 7 Either H or C 16 Only when it is alkyl, R 1a and R 1b at least one of is other than H; However, when the sum of q and t is 2, a)R 2 is other than H, and b) If present, R 6 and R 7 at least one of which is other than H or methyl, or a salt, hydrate, or isomer thereof.

[0119] In other embodiments, the bone forming agent has the formula: [ka] [In the formula, R 1b is C 1~6 is alkoxy; R 2 , H, C 1~6 Alkyl, and C 1~6 haloalkyl; Each R 1a , R 1c , and R 1d are independently H or halogen; However, R 1a , R 1c and R 1d Not more than two of are H; A is, [ka] and; R Nis selected from the group consisting of heterocyclyl and heteroaryl; The heterocyclyl moieties are selected from monocyclic, fused bicyclic, and bridged bicyclic, where the monocyclic heterocyclyl contains 4 to 7 ring members and the fused bicyclic and bridged bicyclic heterocyclyl contains 7 to 10 ring members, each heterocyclyl moiety having 1 to 3 heteroatoms as ring members selected from N, O, and S, each heterocyclyl moiety containing at least one nitrogen atom as a ring member and 1 to 3 R 5 is optionally substituted with a moiety, The heteroaryl moiety contains 5 to 10 ring members, at least one ring member being a nitrogen atom, and 1 to 3 R 5 is optionally substituted with a moiety, Each R 5 -OH, C 1~3 Alkyl, C 1~3 Alkyl-OH, -OC 1~3 Alkyl, C 3~4 Heteroalkyl, C 1~3 Haloalkyl, -OC 1~3 haloalkyl, halogen, and oxo; or a salt or hydrate thereof.

[0120] In some embodiments, the bone forming agent is [ka] or a salt or hydrate thereof.

[0121] IV. Methods for Promoting Bone Formation In another aspect, the present invention provides a method of promoting bone formation and fixation in a subject in need thereof by locally administering to the subject a therapeutically effective amount of a composition of the invention (e.g., a composition comprising a scaffold as described above), optionally together with a composition described herein.

[0122] One of ordinary skill in the art will appreciate that osteoblast mineral deposition (bone formation) can be achieved by local, systemic, or both local and systemic administration. In some embodiments, bone formation is local. A subject in need of local bone formation may have any of a variety of illnesses or disease states, including, but not limited to, weakened bones, fractured bones, or diseases or conditions characterized by low bone mass or insufficient mineralization, as described herein. In some embodiments, a subject is in need of spinal fusion, bone fusion, arthrodesis, or orthopedic, dental, or periodontal synthetic bone grafts or implants. In some embodiments, the invention provides methods of promoting bone formation at the site of an injury or localized condition. In some embodiments, the invention includes methods of fixing bone (e.g., at the site of an injury). In some embodiments, the site of injury is a surgical site. In other embodiments, the injury is a fractured or weakened bone or periodontal disease.

[0123] In some embodiments, bone formation is systemic. Systemic bone formation refers to bone formation throughout the subject and may affect all bones in the subject's body. A subject in need of systemic bone formation may suffer from any of a variety of illnesses or disease states. In some embodiments, the subject suffers from a condition / disease that causes low bone mass / density (either primary or secondary), bone fracture, periodontal disease / condition, or a disease / condition that causes insufficient bone mineralization (e.g., osteogenesis imperfecta or HPP). Low bone mass can be determined by a variety of methods known to those skilled in the art. For example, low bone mass / density can be characterized by a T-score of less than about -0.5. Low bone mass / density diseases / conditions include, but are not limited to, osteoporosis, osteopenia, and osteoporosis pseudoglioma syndrome (OPPG), glucocorticoid-induced low bone mass / density, osteogenesis imperfecta. In some other embodiments, the low bone mass condition / disease may be osteopenia or osteoporosis pseudoglioma syndrome (OPPG), HPP, or other diseases resulting in glucocorticoid-induced low bone mass / density, or secondary low bone density conditions.

[0124] Local and / or systemic bone formation using the compounds or compositions of the present invention can be achieved according to any of a variety of methods. Methods of formulating and administering the compounds and compositions of the present invention (e.g., compounds or compositions of formula I) are described in Section VII, below. In some embodiments, the method of promoting bone formation includes implanting a medical device as described herein (e.g., Section VIII, below) in a subject in need thereof.

[0125] The method of promoting osteoblast mineral deposition and ultimately increasing bone mineralization or density can be used to treat patients with diseases characterized by secondary osteoporosis (low bone mass), including osteomalacia, polyostotic fibrous dysplasia, osteogenesis imperfecta, Paget's disease, rheumatoid arthritis, weightlessness, osteoarthritis, prolonged inactivity or immobility, joint immobilization, osteomyelitis, celiac disease, Crohn's disease, ulcerative colitis, gastrectomy, secondary osteoporosis, amenorrhea, Cushing's disease, Cushing's syndrome, diabetes mellitus, diabetes, eating disorders, hyperparathyroidism, hyperthyroidism, hyperphosphatasia (HPP), hyperprolactinemia, Klinefelter's syndrome, thyroid disease, Turner's syndrome, steroid-induced osteoporosis, stroke or depression-induced osteoporosis, immobility, arthritis, cancer. induced secondary osteoporosis, gonadotropin releasing hormone agonist induced low bone mass, thyroid drug induced low bone mass, Dilantin (phenytoin), Depakote induced low bone mass, chemotherapy induced low bone mass, immunosuppressant induced low bone mass, blood thinner induced low bone mass, Graves' disease, juvenile rheumatoid arthritis, malabsorption syndromes, anorexia nervosa, kidney disease, anticonvulsant treatment (e.g. for epilepsy), corticosteroid treatment (e.g. for rheumatoid arthritis, asthma), immunosuppressant treatment (e.g. for cancer), nutritional deficiencies (especially calcium, vitamin D), excessive exercise leading to amenorrhea (absence of menstruation), smoking, and alcohol abuse, pregnancy-related osteoporosis, copper deficiency, dibasic aminoaciduria type 2, Werner's syndrome, HajduCheney syndrome, juvenile degenerative cortical hyperostosis (hyperostosis) corticalis deformans juvenilis, methylmalonic aciduria type 2, cystathionine beta-synthase deficiency, exemestane, hyperimmunoglobulin E (IgE) syndrome, hemochromatosis, Singleton-Merten syndrome, beta-thalassemia (homozygous), reflex sympathetic osteodystrophy, sarcoidosis, Winchester syndrome, Hallermann-Streiff syndrome (HSS), cyproterone, glycerol kinase deficiency, Bonnet Dechaume Blanc syndromesyndrome), prednisolone, heparin, gerontoderma osteodystrophy, Torg osteolysis syndrome, orchiectomy, Fabry disease, pseudoprogeria syndrome, Wolcott-Rallison syndrome, ankylosing spondylitis, myeloma, generalized infantile hyalinosis, Albright hereditary osteodystrophy, anorexia nervosa, autoimmune lymphoproliferative syndrome, Brown-Séquard syndrome, Diamond-Blackfan anemia, eating disorders, galactorrhea hyperplasia These include, but are not limited to, cholangitis, gonadal dysgenesis, renal conditions, Menkes' disease, menopause, neuritis, ovarian failure due to FSH resistance, familial ovarian failure, premature aging, primary biliary cirrhosis, prolactinoma, familial prolactinoma, renal osteodystrophy, ulcerative colitis, low body weight, Werner's syndrome, bone tumor, bone cancer, brittle bone disease, osteonecrosis, congenital osteogenesis imperfecta, tardy osteogenesis imperfecta, osteogenesis imperfecta, glucocorticoid-induced osteopenia / osteoporosis, and periodontal disease.Those skilled in the art will understand that other types of conditions, diseases, and treatments can also cause osteoporosis.

[0126] Bone formation can be measured according to any of various methods known to those skilled in the art.Methods of measuring bone formation include, but are not limited to, μCT (microCT), dual-energy X-ray absorption (bone density), ultrasound, QCT, SPA, DPA, DXR, SEXA, QUS, X-ray, use of human eye during surgical operation, Alizarin Red S, serum osteocalcin, serum alkaline phosphatase, serum bone Gla protein (BGP), bone mineral content, bone ash weight, serum calcium, serum phosphorus, tantalum marker, and serum IGF1.

[0127] Many indicators of bone formation can be used to measure and / or quantify the amount of bone formation, including bone density. In some embodiments, bone formation can be indicated by a 0.1% increase in bone density. In other embodiments, bone growth can be indicated by a 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 14%, 16%, 18%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000% or greater increase in bone density. Bone density can be measured by a variety of different methods, including T-score and Z-score. The Z-score is the number of standard deviations above or below the mean for the patient's age and sex. The T-score is the number of standard deviations above or below the mean for a healthy 30-year-old adult of the same sex as the patient. Low bone mass is characterized by a T-score between 1 and 2.5. Osteoporosis is characterized by a T-score below 2.5. An improvement in the T-score or Z-score indicates bone growth. Bone density can be measured at various locations in the skeleton, such as the spine or hips. One of skill in the art will appreciate that other methods of measuring bone density are useful in the present invention.

[0128] V. Methods of Treating Bone Loss In another aspect, the present invention provides a method of treating bone loss by locally administering to a subject suffering from bone loss a therapeutically effective amount of a composition of the present invention (e.g., a composition described herein, or a scaffold or composition optionally comprising another bone forming agent described herein).

[0129] Bone density in an individual can be described by the net loss (bone resorption) and gain (bone formation) of bone mass. In individuals with bone loss, the net amount of bone resorption exceeds the amount of bone formation, resulting in bone loss. In a particular embodiment of the present invention, it is contemplated that bone loss can be treated by inhibiting or reducing bone resorption while stimulating or promoting bone formation.

[0130] Anti-resorptive agents are compounds that slow the process of bone resorption. Anti-resorptive agents include, but are not limited to, RankL inhibitors, denosumab, Prolia, cathepsin-K modulators, alendronate, fosamax, selective estrogen receptor modulators (SERMs), calcium, estrogen, bisphosphonates, and calcitonin.

[0131] The compositions of the present invention treat bone loss by promoting bone formation. The administration of the compounds of the present invention sequentially or in combination with one or more anti-resorptive agents inhibits or reduces the rate of bone resorption and stimulates the rate of bone formation.

[0132] The compositions of the present invention and the anti-resorptive agents described herein may be administered sequentially or in combination.

[0133] The compositions of the present invention treat bone loss by promoting bone formation. In some embodiments, when the compounds of the present invention are administered sequentially with one or more anti-resorptive agents, the rate of bone resorption is inhibited or reduced and the amount of bone formation is maintained.

[0134] The compositions of the present invention can be administered continuously to a patient treated with an anti-resorptive agent, or by continuously administering one or more anti-resorptive agents to a patient, the rate of bone resorption is inhibited or reduced and bone formation is maintained.

[0135] The subject treated with the compositions and methods of the invention can be any mammal, e.g., a human or a non-human mammal, such as a primate, dog, cat, horse, cow, goat, sheep, pig, mouse or rat, or any commercially important animal or domestic animal.

[0136] In some embodiments, the subject treated according to the methods of the invention is an individual who has been or is being administered an anti-resorptive therapy. For example, in some embodiments, the anti-resorptive therapy can be administered simultaneously with the compositions of the invention. In some embodiments, the anti-resorptive therapy and therapy with the compositions of the invention are administered sequentially (either anti-resorptive therapy preceding therapy with the compositions of the invention, or therapy with the compositions of the invention preceding the anti-resorptive therapy). In some embodiments, the individual may have been previously treated with an anti-resorptive agent. In some embodiments, the individual treated according to the methods of the invention has not been treated with an anti-resorptive agent. In some embodiments, the individual is treated with an anti-resorptive agent after being treated with a composition of the invention.

[0137] In some embodiments, the individual treated according to the method of the invention is an individual who has been or is being administered a combination of an anti-resorptive and / or bone anabolic therapeutic agent. For example, in some embodiments, the anti-resorptive and / or bone anabolic therapy can be administered simultaneously with the composition of the invention. In some embodiments, the anti-resorptive and / or bone anabolic therapy and therapy with the composition of the invention are administered sequentially (either the anti-resorptive therapy preceding therapy with the composition of the invention, or therapy with the composition of the invention preceding the anti-resorptive therapy). In some embodiments, the individual may have been previously treated with an anti-resorptive and / or bone anabolic agent. In some embodiments, the individual may be simultaneously treated with an anti-resorptive and / or bone anabolic agent during a first portion of a treatment course of a compound or composition of the invention, but may discontinue treatment with the anti-resorptive and / or bone anabolic agent during a second portion of the treatment course. In some embodiments, the individual treated according to the method of the invention has not been treated with an anti-resorptive and / or bone anabolic agent. In some embodiments, the individual is treated with an anti-resorptive and / or bone anabolic agent after being treated with a composition of the invention.

[0138] In some embodiments, the compositions of the invention are administered systemically, hi some embodiments, the compounds and compositions of the invention are administered locally.

[0139] The compounds of the present invention can also be included in sustained release formulations for long-term treatment after a single dose.In one embodiment, the formulation is prepared in the form of microspheres.Nanoparticles / microspheres can be prepared as homogeneous matrices of compounds with biodegradable controlled release materials, optionally with additional medicaments as needed for treatment.Nanoparticles / microspheres are preferably prepared with sizes suitable for penetration and / or injection, and are injected systemically or directly into the treatment site.

[0140] Some sustained release embodiments include biodegradable and / or slowly dissolving polymeric materials, including polyvinylpyrrolidone, low and medium molecular weight hydroxypropylcellulose and hydroxypropylmethylcellulose, cross-linked sodium carboxymethylcellulose, carboxymethylstarch, collagen, potassium methacrylate divinylbenzene copolymer, polyvinyl alcohol, starch, starch derivatives, microcrystalline cellulose, ethylcellulose, methylcellulose, and cellulose derivatives, β-cyclodextrin, captisol, poly(methyl vinyl ether / maleic anhydride), glucans, scierozlucans, mannans, xanthan, alzinic acid and its derivatives, dextrin derivatives, glyceryl monostearate, semi-synthetic glycerides, glyceryl palmitostearate, glyceryl behenate, polyvinylpyrrolidone, gelatin, magnesium stearate, stearic acid, sodium stearate, talc, sodium benzoate, boric acid, and colloidal silica.

[0141] The sustained release agents of the present invention may also include adjuvants such as starch, pregelled starch, calcium phosphate mannitol, lactose, saccharose, glucose, sorbitol, microcrystalline cellulose, gelatin, polyvinylpyrrolidone, methylcellulose, starch solution, ethylcellulose, gum arabic, gum tragacanth, magnesium stearate, stearic acid, colloidal silica, glyceryl monostearate, hydrogenated castor oil, waxes, and mono-, di-, and tri-substituted glycerides. The sustained release agents may also be prepared as generally described in WO 94 / 06416.

[0142] A. Local Delivery The compositions of the present invention are designed to be administered locally. Local administration of the compositions of the present invention can be used, for example, in fracture healing, fusion surgery (e.g., arthrodesis), orthopedic reconstruction, and periodontal repair. In some embodiments, local administration includes administering the composition in conjunction with a second material that can maintain the composition at the application site in vivo or provide structural loading. In some embodiments, the second material is biocompatible, a matrix, biodegradable or resorbable in vivo, and / or sufficiently porous to allow cell infiltration. In some embodiments, the compositions of the present invention (e.g., compositions comprising a compound of formula I) are administered locally at the surgical site and / or administered using an implantable medical device.

[0143] Scaffolds or matrices for use in delivering the compounds of the present invention may include synthetic materials, biological materials, or combinations thereof. In some embodiments, the scaffolds or matrices include naturally occurring polymers, synthetic biodegradable polymers, synthetic non-biodegradable polymers, bioceramics, bioactive glasses, or combinations thereof. Natural and synthetic polymers, bioceramics, and bioactive glasses for use in scaffolds are known in the art. See, for example, Dhandayuthapani et al., International Journal of Polymer Science, Vol. 2011, Article ID 290602 (2011), which is incorporated herein by reference. Natural polymers include, but are not limited to, proteins (e.g., silk, collagen, gelatin, fibrinogen, elastin, keratin, actin, and myosin), polysaccharides (e.g., cellulose, amylose, dextran, chitin, chitosan, and glycosaminoglycans), and polynucleotides (e.g., DNA and RNA). Synthetic polymers include, but are not limited to, PLA, PGA, PLLA, PLGA, PCL, PLDLA, PDS, PGCL, PEA, PCA, PDLLA, PEU, and PBT. Bioceramics and bioactive glasses include, but are not limited to, HAP, TCP, CP ceramic, BCP, and TCP and 45S5. In some embodiments, the scaffold or matrix is ​​a hydrogel scaffold, a fibrous scaffold, a microsphere scaffold, a polymer-bioceramic composite scaffold, or an acellular scaffold.

[0144] In some embodiments, the osteoconductive matrix comprises an osteoinductive agent and, optionally, a structural support. The osteoinductive agent can be any agent that promotes bone formation. In some embodiments, the osteoinductive agent is a bone allograft, a bone autograft, demineralized bone, bone marrow aspirate, or periodontal ligament cells.

[0145] B. Combination Therapy In carrying out the method of the present invention, the pharmaceutical composition may be used alone or in combination with other therapeutic or diagnostic agents. Additionally, the medical devices described herein include the use of the compositions described herein alone or in combination with other therapeutic or diagnostic agents. Additional drugs used in the combination protocol of the present invention may be administered separately, or one or more drugs used in the combination protocol may be administered together, such as by co-infusion. When one or more drugs are administered separately, the timing and schedule of administration of each drug may differ. Other therapeutic or diagnostic agents may be administered simultaneously with the compounds of the present invention, separately, or at different times.

[0146] In some embodiments, a compound or composition described herein (e.g., a composition described herein) is administered in combination with one or more other therapeutic agents. When a compound of the invention is combined with another agent, the two can be administered simultaneously or separately. Simultaneous administration includes administration of the other agent within 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, or 24 hours, as well as within 1-7 days (e.g., 1, 2, 3, 4, 5, 6, or 7 days), 1-4 weeks (e.g., 1, 2, 3, or 4 weeks), or 1 or 18 months (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 months) of administration of a compound of the invention. Concomitant administration also includes administering the other agent and the compound of the invention simultaneously, at about the same time (e.g., within about 1, 5, 10, 15, 20, or 30 minutes of each other, or on the same day, or the same week, or the same month), or consecutively in any order. In some embodiments, concomitant administration includes administering another agent (e.g., an antiresorptive agent) for a period of time (e.g., weeks, months, or years), followed by administering a composition described herein (e.g., for days, weeks, months, or years), followed by administering the other agent (e.g., an antiresorptive agent) alone or in combination with a composition described herein. In some embodiments, the other agent and the compound of the invention can each be administered once daily, or two, three, or more times daily to provide the preferred dosage per day.

[0147] In some embodiments, simultaneous administration can be achieved by co-formulation, i.e., preparing a single pharmaceutical composition that includes both the compound of the invention and the second therapeutic agent (e.g., an anti-resorptive agent), hi other embodiments, the compound of the invention and the second therapeutic agent are formulated separately.

[0148] The one or more other therapeutic agents can be delivered by any suitable means. The pharmaceutical preparation is preferably in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate amounts of anti-resorptive agent and / or compound of the present invention. The unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparation (e.g., packaged tablets, capsules, and powders in vials or ampoules). The unit dosage form can also be a capsule, tablet, cachet, patch, or lozenge itself, or the appropriate number of any of these in packaged form.

[0149] The one or more other therapeutic agents can be present in any suitable amount, which may depend on a variety of factors, including, but not limited to, the weight and age of the subject, the state of the disease, etc. Suitable dosage ranges of the one or more other therapeutic agents in combination with the compounds or compositions of the present invention include about 0.0001 μg to about 10,000 mg, or about 0.0001 μg to about 1000 mg, or about 0.0001 μg to about 500 mg, or about 0.0001 μg to about 1000 μg, 0.1 μg to about 10,000 mg, or about 0.1 μg to about 1000 mg, or about 0.1 μg to about 500 mg, or about 0.1 μg to about 1000 μg. Or about 1 μg to about 1000 mg, or about 1 μg to about 500 mg, or about 1 μg to about 50 mg, or about 1 μg to about 1000 μg, or about 10 μg to about 1000 mg, or about 10 μg to about 500 mg, or about 10 μg to about 50 mg, or about 0.1 mg to about 10,000 mg, or about 1 mg to about 1000 mg, or about 10 mg to about 750 mg, or about 25 mg to about 500 mg, or about 50 mg to about 250 mg. Suitable dosages of one or more other therapeutic agents in combination with a compound or composition of the invention include about 0.01, 0.1, 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1250, 1500, 1750 or 2000 mg.

[0150] The one or more other therapeutic agents and the compounds or compositions of the invention may be present in the compositions of the invention in any suitable weight ratio, for example, about 1:100 to about 100:1 (w / w), or about 1:50 to about 50:1, or about 1:25 to about 25:1, or about 1:10 to about 10:1, or about 1:5 to about 5:1 (w / w), or about 1:1 (w / w). Other doses and dose ratios of the antiresorptive agent and the compounds of the invention are suitable in the compositions and methods of the invention.

[0151] The compositions may also contain other compatible therapeutic agents. The compounds described herein may be combined with each other, with other active agents, or with adjuvants that may not be effective alone but may contribute to the effectiveness of the active agent.

[0152] In some embodiments, the individual treated according to the methods of the invention is administered a composition as described herein in combination with or sequentially with an anti-resorptive agent. Anti-resorptive agents include those that slow or block bone resorption. Administering a compound or composition as described herein and an anti-resorptive agent can promote local bone growth and / or systemic bone growth. In some embodiments, administering a compound or composition as described herein and an anti-resorptive agent promotes systemic bone growth. Bone growth can be achieved by increasing bone mineral content, increasing bone density, and / or growing new bone. In other embodiments, systemic bone growth is achieved by local application of a compound or composition as described herein and an anti-resorptive agent.

[0153] Antiresorptive agents useful in the methods of the invention include, but are not limited to, denosumab, Prolia, RankL inhibitors, bisphosphonates (e.g., Fosamax, denosumab, Prolia, Actonel, or Reclast, alendronate, Bonviva™, Zometa™, olpadronate, neridronate, skelid, Bonefos), selective estrogen receptor modulators (SERMs) or analogs (e.g., Evista), calcitonin, calcitonin analogs (e.g., Miacalcic), parathyroid hormone, calcilytics, calcimeter receptor agonists (e.g., cinacalcet), statins, anabolic steroids, lanthanum and strontium salts, and sodium fluoride, vitamin D or vitamin D analogs, CatK inhibitors, prostaglandin inhibitors, or phosphodiesterase inhibitor type E.

[0154] In some embodiments, the anti-resorptive agent is denosumab.

[0155] The bisphosphonate useful in the method of the present invention can be any suitable bisphosphonate. In some embodiments, the bisphosphonate is nitrogen-containing, such as pamidronate (APD, Aredia), neridronate, olpadronate, alendronate (Fosamax), ibandronate (Boniva), risedronate (Actonel) and zoledronate (Zometa). In other embodiments, the bisphosphonate is non-nitrogenous, such as etidronate (Didronel), clodronate (Bonefos, Loron) and tiludronate (Skerid). Those skilled in the art will understand that other bisphosphonates are also useful in the present invention.

[0156] The SERM useful in the method of the present invention can be any suitable SERM. In some embodiments, the SERM can be clomiphene, raloxifene, tamoxifen, toremifene, bazedoxifene, lasofoxifene or ormeloxifene. Those skilled in the art will understand that other SERMs are also useful in the present invention.

[0157] The anti-resorptive agent can also be any suitable calcitonin analog or cathepsin K inhibitor. In some embodiments, calcitonin analogs useful in the methods of the present invention include, but are not limited to, miacalci. Those skilled in the art will appreciate that other calcitonin analogs are useful in the present invention.

[0158] The vitamin D analogues useful in the method of the present invention can be any suitable vitamin D analogue. In some embodiments, the vitamin D analogues useful in the method of the present invention include, but are not limited to, vitamin D1 (the molecular compound of ergocalciferol and lumisterol, 1:1), vitamin D2 (ergocalciferol or calciferol), vitamin D3 (cholecalciferol), vitamin D4 (22-dihydroergocalciferol) and vitamin D5 (cytocalciferol). Those skilled in the art will understand that other vitamin D analogues are useful in the present invention.

[0159] RankL inhibitors useful in the present invention include any compound that inhibits the activity of RankL.For example, RankL inhibitors include, but are not limited to, human monoclonal antibodies denosumab or prolia.Those skilled in the art will understand that other RankL inhibitors are useful in the present invention.

[0160] In some embodiments, an individual treated according to the methods of the invention is administered a composition described herein in combination with or sequentially with an anabolic agent, including but not limited to parathyroid hormone (PTH) or an analog thereof, P15, a sclerostin inhibitor, a sclerostin antibody, a bone morphogenetic protein (BMP) or a BMP agonist, a population of bone marrow stem cells, or a population of mesenchymal stem cells.

[0161] In some embodiments, the anabolic agent is parathyroid hormone (PTH) or an analog thereof (e.g., teriparatide (Forteo). In some embodiments, the anabolic agent is P15 or an analog thereof. In some embodiments, the anabolic agent is a sclerostin antibody (Mab) inhibitor, in some embodiments selected from romosozumab, BPS804, BA058, brosozumab, and AbD09097. In some embodiments, the BMP is selected from the group consisting of BMP2, BMP7, BMP4, BMP5, and BMP6. In some embodiments, the BMP agonist is a compound described in Vrijens K, et al. PLoS One. 2013;8(3):e59045, the contents of which are incorporated by reference for all purposes. In some embodiments, the anabolic agent is a population of bone marrow stem cells. In some embodiments, the anabolic agent is a population of mesenchymal stem cells.

[0162] VI. Medical Devices In some embodiments, the present invention provides a medical device formed from a structural support, where an implantable portion of the structural support is adapted to be permanently implanted within a subject, where the implantable portion is attached to bone, and where the structural support carries at least a partial coating comprising a composition described herein, hi some embodiments, the medical device is an orthopedic or periodontal medical device.

[0163] Another aspect of the invention relates to a medical implant. Such medical devices and implants include osteogenic devices and methods of use for repairing endochondral bone and osteochondral defects, as taught, for example, in U.S. Patent Application Publication No. 20060177475, published Aug. 10, 2006, to David Rueger et al., as well as described in U.S. Patent Nos. 6,190,880, 5,344,654, 5,324,819, 5,468,845, 6,949,251, 6,426,332, and 5,656,593, and U.S. Patent Application Publication Nos. 2002 / 0169122, 2002 / 0187104, 2006 / 0252724, and 2007 / 0172479, the subject matter of which is incorporated herein by reference.

[0164] These medical devices generally provide a structural support with an implantable portion that is preferentially adapted to mechanically engage bone and / or cartilage, as taught, for example, in US Patent Publication No. 2006 / 0178752, published Aug. 10, 2006, by Joseph Vaccarino III et al., the subject matter of which is incorporated herein by reference. These bone implants desirably contain an active agent in at least a portion thereof. As shown in US Patent Publication No. 2006 / 0188542, published Aug. 24, 2006, by John Dennis Bobyn et al., the subject matter of which is incorporated herein by reference, the active agent is preferably formulated to be locally deliverable to bone adjacent to the implant in a sustained release or at least two-stage release scheme. In the latter, a first phase rapidly releases a first amount of the active agent, and a second and subsequent phases slowly release a second amount of the active agent, thereby modulating the bone formation stimulated by the active agent.

[0165] Medical devices such as bone implants feature an implantable portion carrying a compound or composition of the invention (e.g., a composition described herein) to promote more rapid and more complete bone formation in situ. It may be desirable for the implantable portion of the medical device to be at least partially or completely coated or impregnated with a compound or composition of the invention. In some embodiments, the medical device is externally coated with a compound or composition as described herein. In some embodiments, the external coating completely coats the implantable portion of the structural support. In some embodiments, the structural support (e.g., a matrix or scaffold) comprises within the support, i.e., internally, a compound or composition as described herein. In some embodiments, the structural support (e.g., a matrix or scaffold) comprises an external coating of a compound or composition as described herein and comprises within the support, i.e., internally, a compound or composition.

[0166] The medical devices of the present invention include pins, rods, screws, plates, cages, nails, orthopedic and / or dental implants. In some embodiments, the medical devices are made of materials including metals, polymers, or ceramics, or combinations thereof. Metals useful for manufacturing the medical devices of the present invention include, but are not limited to, cobalt, chromium, chromium, stainless steel, titanium, titanium alloys, tantalum, trabecular metals. Polymers useful for manufacturing the medical devices of the present invention include, but are not limited to, ultra-high molecular weight polyethylene or high density polyethylene. In some embodiments, carbon fibers are combined with polyethylene. Additional useful polymers are described below. Ceramics useful for manufacturing the medical devices of the present invention include, but are not limited to, aluminum oxide, calcium phosphate, hydroxyapatite, zirconium oxide, silicon oxide.

[0167] In some other embodiments, the implantable portion of the structural support comprises an osteoconductive matrix. The matrix material can promote bone growth. This may be desirable for materials such as teeth and artificial bone graft portions. Alternatively, when the implantable portion is load-bearing and is formed, for example, of stainless steel, it may be desirable for these implantable portions to be formed with a coating of the compound or composition of the present invention. In that case, it may be desirable to also provide a separate matrix material that promotes the formation of new bone growth.

[0168] In some embodiments, the matrix comprises particles of porous material. The pores are preferably of a size that allows the migration of progenitor cells into the matrix and subsequent differentiation and proliferation. In some embodiments, the pore size of the matrix is ​​at least 5 μm, such as at least 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 110, 115, 120, 125, 150, 175, 200, 250, 300, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1250, 1500, 1750 or 2000 μm. In some embodiments, the scaffold or matrix comprises a mesh structure, a foam structure, a sponge structure, or a fiber structure.

[0169] Scaffolds or matrices for use in the devices described herein may include synthetic and / or biological materials. In some embodiments, the scaffolds or matrices include naturally occurring polymers, synthetic biodegradable polymers, synthetic non-biodegradable polymers, bioceramics, bioglasses, bioactive glasses, biocomposites, or combinations thereof. Natural and synthetic polymers, bioceramics, and bioglasses for use in scaffolds are known in the art. See, for example, Dhandayuthapani et al., International Journal of Polymer Science, Vol. 2011, Article ID 290602 (2011), which is incorporated herein by reference. Natural polymers include, but are not limited to, proteins (e.g., silk, collagen, gelatin, fibrinogen, elastin, keratin, actin, and myosin), polysaccharides (e.g., cellulose, amylose, dextran, chitin, chitosan, and glycosaminoglycans), and polynucleotides (e.g., DNA and RNA). Synthetic polymers include, but are not limited to, PLA, PGA, PLLA, PLGA, PCL, PLDLA, PDS, PGCL, PEA, PCA, PDLLA, PEU, and PBT. Bioceramics and bioactive glasses include, but are not limited to, HAP, TCP, CP ceramic, BCP, TCP, and 45S5. In some embodiments, the scaffold or matrix is ​​a hydrogel scaffold, a fibrous scaffold, a microsphere scaffold, a polymer-bioceramic composite scaffold, or an acellular scaffold.

[0170] In some embodiments, suitable matrices include those comprising composite biomaterials having a sponge-like structure, such as those containing phosphophoryn and / or collagen, as taught in U.S. Patent Application Publication No. 2006 / 0188544 to Takashi Saito, published Aug. 24, 2006, the contents of which are incorporated herein by reference. Such coatings include, for example, single-layer and multi-layer coatings, which can be prepared by conventional methods, including those taught in U.S. Patent Application Publication No. 2006 / 0204542 to Zongtao Zhang et al., published Sep. 14, 2006, and U.S. Patent Nos. 6,949,251, 5,298,852, 5,939,039, and 7,189,263, the subject matter of which is incorporated herein by reference.

[0171] In some embodiments, the matrix is ​​an osteoconductive matrix. In some embodiments, the osteoconductive matrix includes an osteoinductive agent, such as bone allograft, bone autograft, bone marrow aspirate, demineralized bone, or periodontal ligament cells, or a combination thereof. In some other embodiments, the osteoconductive matrix can be calcium salt, calcium sulfate, biphasic calcium phosphate, calcium phosphate, calcium phosphate cement, hydroxyapatite, coral-based hydroxyapatite (HA), dicalcium phosphate, tricalcium phosphate (TCP), calcium carbonate, collagen, plaster of Paris, phosphophorin, borosilicate, biocompatible ceramic, calcium phosphate ceramic, polytetrafluoroethylene, sulfate, borosilicate, bioactive glass, Mastergraft variant, Vitoss variant, cement hydrogel, or a combination thereof. Those skilled in the art will appreciate that other osteoconductive matrices and osteoinductive agents are useful in the present invention.

[0172] In some embodiments, the medical device described herein comprises both the composition described herein and an additional therapeutic agent. Suitable additional therapeutic agents include the combinations discussed above. For example, the medical device may comprise the composition described herein in combination with an anabolic agent. In some embodiments, the medical device described herein comprises the composition described herein in combination with a bone morphogenetic protein (BMP) or a BMP agonist. In some embodiments, the BMP is selected from the group consisting of BMP2, BMP7, BMP4, BMP5, and BMP6. In some embodiments, the BMP agonist is a compound described in Vrijens K, et al. PLoS One. 2013;8(3):e59045, the contents of which are incorporated by reference for all purposes.

[0173] VII. SPECIFIC EMBODIMENTS OF THE DISCLOSURE Embodiment 1. a) a scaffold comprising hydroxyapatite and tricalcium phosphate in a ratio of 0 / 100 to 15 / 85, collagen, and bioactive glass, the bioactive glass being uniformly dispersed both inside and on the surface of the scaffold; b) Formula I: [ka] [In the formula, X is CR 3b and N, where N is optionally oxidized to the corresponding N-oxide; Y is CR 3c and N, where N is optionally oxidized to the corresponding N-oxide; Z is CR 3d and N, where N is optionally oxidized to the corresponding N-oxide; With the proviso that at least one of X, Y and Z is N or the corresponding N-oxide; A is, [ka] and; R N is selected from the group consisting of heterocyclyl and heteroaryl; The heterocyclyl moieties are selected from monocyclic, fused bicyclic, and bridged bicyclic, where the monocyclic heterocyclyl contains 4 to 7 ring members and the fused bicyclic and bridged bicyclic heterocyclyl contains 7 to 10 ring members, each heterocyclyl moiety having 1 to 3 heteroatoms as ring members selected from N, O, and S, each heterocyclyl moiety containing at least one nitrogen atom as a ring member and 1 to 3 R 6 is optionally substituted with a moiety, The heteroaryl moiety contains 5 to 10 ring members, at least one ring member being a nitrogen atom, and 1 to 3 R 6 is optionally substituted with a moiety, Each R 2 , R 3b , R 3c and R 3d H, halogen, C 16 Alkyl, C 16 Haloalkyl, C 26 Alkenyl, C 26 Alkynyl, C 16 Alkoxy, C 16 Haloalkoxy, C 16 Alkyl OH, OC 16 AlkylOH, C 3~6 Cycloalkyl-C 1~4 independently selected from the group consisting of alkoxy, and -OH; R 6 -OH, C 1~3 Alkyl, C 13 AlkylOH, -OC 1~3 Alkyl, C 3~4 Heteroalkyl, C 1~3 Haloalkyl, -OC 1~3 or a salt, hydrate, prodrug, or isomer thereof; A sterile composition for bone formation, which is sterilized and packaged.

[0174] Embodiment 2. A composition for bone formation comprising a scaffold, the scaffold being a scaffold of hydroxyapatite (HA) and tricalcium phosphate (TCP) in a ratio of 0 / 100 to 15 / 85, collagen, and bioactive glass, the bioactive glass being uniformly dispersed both inside and on the surface of the scaffold, and the composition being sterilized and packaged.

[0175] Embodiment 3. The composition of embodiment 1 or 2, wherein the scaffold is in the form of granules, strips, blocks, spheres, putty, or liquid cement.

[0176] Embodiment 4. The composition of embodiment 1 or 2, wherein the hydroxyapatite and tricalcium phosphate are in a ratio of about 0 / 100, 5 / 95, or 10 / 90.

[0177] Embodiment 5. The composition of embodiment 1 or 2, wherein the bioactive glass has a particle size of about 50 microns to about 500 microns.

[0178] Embodiment 6. The composition of embodiment 1 or 2, wherein the bioactive glass has a particle size of about 90 microns to about 250 microns.

[0179] Embodiment 7. The composition of embodiment 1 or 2, which is moldable.

[0180] Embodiment 8. The composition of embodiment 1 or 2, which has been sterilized using a method selected from the group consisting of gamma radiation, E-beam radiation, UV radiation, steam, dry heat, plasma, and chemical sterilization (ether, ethanol, iodine, or PAA).

[0181] Embodiment 9. Formula Ia, Ib, Ic, or Id: [ka] 2. The composition of embodiment 1, having the following structure:

[0182] Embodiment 10.R 2 H, halogen, C 16Alkyl, C 16 Haloalkyl, C 16 Alkoxy and C 16 The composition of embodiment 9, wherein the alkyl group is selected from the group consisting of haloalkoxy.

[0183] Embodiment 11.R 2 But halogen, C 16 Alkyl, C 16 Haloalkyl and C 16 The composition of embodiment 9, wherein the alkyl group is selected from the group consisting of alkoxy.

[0184] Embodiment 12.R 2 But, C 1~6 Alkyl or C 1~6 The composition of embodiment 9, wherein the alkyl group is haloalkyl.

[0185] Embodiment 13.R 2 is CH3 or CF3.

[0186] Embodiment 14.R 2 The composition of embodiment 9, wherein is CH3.

[0187] Embodiment 15.R 2 The composition of embodiment 9, wherein is CF3.

[0188] Embodiment 16.R N is heterocyclyl or heteroaryl.

[0189] Embodiment 17.R N The composition of embodiment 16, wherein is monocyclic heterocyclyl.

[0190] Embodiment 18.R N but, [ka] 18. The composition of embodiment 17, wherein

[0191] EMBODIMENT 19. [ka] The composition of embodiment 18, selected from the group consisting of: or a salt, hydrate or prodrug thereof.

[0192] Embodiment 20. The composition of any one of embodiments 1-19, further comprising an additional bone forming agent.

[0193] Embodiment 21. The composition of embodiment 20, wherein the bone forming agent is selected from the group consisting of P15, BMP2, BMP7, BMP4, PTH, anti-sclerostin antibodies, anti-sclerostin and anti-resorptive agents.

[0194] Embodiment 22. A method for promoting bone formation in a subject in need thereof, comprising locally administering to the subject an effective amount of a composition described in any one of embodiments 1 to 21, thereby promoting bone formation in the subject.

[0195] Embodiment 23. The method of embodiment 22, wherein bone formation is promoted at a surgical site related to an injury or localized condition.

[0196] Embodiment 24. The method of embodiment 23, wherein bone formation is promoted at a surgical site selected from the group consisting of fractures and weakened bones.

[0197] Embodiment 25. The method of embodiment 23, wherein the subject is in need of spinal fusion surgery, arthrodesis surgery, or an orthopedic or periodontal synthetic bone graft or implant.

[0198] Embodiment 26 The method of embodiment 22, wherein the subject has a low bone mass / density condition, a fracture, or periodontal disease.

[0199] Embodiment 27. The method of embodiment 26, wherein the low bone mass condition is selected from osteoporosis, osteopenia, osteogenesis imperfecta (OI), osteoporosis pseudoglioma syndrome (OPPG), and secondary low bone conditions.

[0200] Embodiment 28. The method of embodiment 27, wherein the low bone mass condition is selected from the group consisting of osteoporosis, osteopenia, and osteoporosis pseudoglioma syndrome (OPPG).

[0201] Embodiment 29 The method of embodiment 22, further comprising administering to the subject an additional osteoconductive matrix component.

[0202] Embodiment 30. The method of embodiment 29, wherein the additional osteoconductive matrix component is selected from the group consisting of bone allograft, bone autograft, and periodontal ligament cells.

[0203] Embodiment 31. The method of embodiment 30, wherein the additional osteoconductive matrix component is selected from the group consisting of calcium salts, calcium sulfate, calcium phosphate, calcium phosphate cement, hydroxyapatite, coral-based hydroxyapatite (HA), dicalcium phosphate, tricalcium phosphate (TCP), calcium carbonate, collagen, plaster of Paris, phosphophoryn, borosilicate, biocompatible ceramics, calcium phosphate ceramics, demineralized bone matrix, biphasic calcium phosphate, biocomposite, tantalum, titanium, polytetrafluoroethylene, sulfates, hydrogels, and combinations thereof.

[0204] Embodiment 32 The method of embodiment 22, wherein the composition is administered sequentially or in combination with an anti-resorptive agent.

[0205] Embodiment 33 The method of embodiment 32, wherein the composition is administered topically to a subject being treated with an anti-resorptive drug or a subject who has previously been treated with an anti-resorptive drug.

[0206] Embodiment 34. The method of embodiment 32, wherein the antiresorptive agent is selected from the group consisting of denosumab, Prolia, a RankL inhibitor, a bisphosphonate, a selective estrogen receptor modulator (SERM), calcitonin, a calcitonin analog, vitamin D, a vitamin D analog, and a cathepsin K inhibitor.

[0207] Embodiment 35. A method of treating bone loss in a subject in need thereof, comprising administering to the subject a therapeutically effective composition according to embodiment 36, either sequentially or in combination with an anti-resorptive agent, thereby treating bone loss in the subject.

[0208] VIII. Examples The following examples are offered to illustrate, but not to limit the claimed invention.

[0209] Compounds used in the examples below and useful in the compositions and methods described herein can be obtained using the methods described in WO 2020 / 037001, WO 2020 / 037004, and WO 2014 / 153203, the contents of which are incorporated herein by reference.

[0210] Example 1: Preparation of scaffolds This example provides instructions for preparing the scaffolds described in this disclosure.

[0211] Step 1 - Addition of Bioactive Glass. For each cc of scaffold (including HA, TCP and collagen available from commercial sources), hydrate with up to 1.48 mL dd-water / cc scaffold so that the scaffold is flexible. Add 125 mg of bioactive glass (BA) and massage into the flexible scaffold until evenly distributed throughout. Mold / form the scaffold into the desired shape and dimensions (i.e., blocks, cylinders, strips, spheres, etc.) and allow to dry and resolidify for 24 hours or more depending on overall size and thickness. The scaffold and BA are presented here as a single product.

[0212] Step 2 - Addition of API. Solid API is placed in water with stirring (i.e. sonication) to obtain a 1.8 mM solution. For each cc of scaffold+BA, add 666.3 μL of 1.8 mM API. Allow API to crystallize and dry within scaffold for 24 hours or more depending on overall size and thickness.

[0213] Example 2: Bone formation assay Mineralization (crystalline calcium phosphate formation) represents an in vitro model of bone formation. It has been previously shown that sclerostin inhibits mineralization in MC3T3-E1 (mouse calvaria) osteoblasts using an assay that quantifies the amount of mineralization by measuring total calcium after solubilization of deposited crystalline calcium phosphate. Li et al., J Bone Miner Res 24:578-588 (2008). According to the protocol described in Li et al., the compositions prepared according to Example 1 or mixtures of the composition components described are assayed for their ability to rescue the inhibition of mineralization by sclerostin in MC3T3 osteoblasts. This assay was used in the examples listed below.

[0214] Example 3: Scaffold size and ratio of hydroxyapatite (HA) to tricalcium phosphate (TCP) This example shows the examination of HA to TCP ratios and the effect of scaffold size on mineralization.

[0215] A 15:85 HA to TCP scaffold was prepared and tested using the mineralization assay described in Example 2. Figure 1 shows that ARS mineralization is reduced in the presence of a 15% HA / 85% TCP scaffold. Column 1 represents wild-type mineralization, where cells have no additives (sclerostin, O20221-1, scaffold). Addition of ectopic sclerostin inhibits normal mineralization (column 3). Positive control O20221-1 in the presence of sclerostin restores normal mineral (compare columns 3 and 5). 15% HA / 85% TCP scaffold alone is unable to produce 100% wild-type mineral (compare column 1 to column 2), and in the presence of sclerostin is unable to restore 100% wild-type mineral (column 4). O20221-1 loaded with a 15% HA / 85% TCP scaffold is unable to restore normal mineral (column 6 compared to column 1).

[0216] Further studies were performed to test the effect of scaffold size on mineralization. Figure 2 shows that by increasing the 15% HA / 85% TCP scaffold size, mineralization of ARS is decreased. Column 1 represents wild type mineralization, where cells have no additives (sclerostin, O20221-1, scaffold or granules). In column 2, sclerostin inhibits wild type mineralization. Addition of O20221-1 in the presence of sclerostin restores normal mineral (column 3). Decreasing the size of the scaffold from 0.12cc to 0.01cc restores the decreased mineral (column 7) to wild type mineral levels (dose response and columns 4-7). The 15% HA / 85% TCP scaffold shows a decrease in mineral as the scaffold size is increased from 0.01cc to 0.12cc (compare column 4 to 1).

[0217] Using the mineralization assay described in Example 2, scaffolds with various ratios of HA:TCP were tested. Figure 3 shows that increasing the percentage of HA content reduces ARS mineralization. Column 1 represents wild-type mineralization, where cells have no addition (sclerostin, O20221-1, scaffold or granules). In column 2, sclerostin inhibits wild-type mineralization. Addition of O20221-1 in the presence of sclerostin restores normal mineral (column 3). Addition of 15% HA / 85% TCP scaffold alone shows a reduction in wild-type mineral (compare column 4 to 1). Increasing concentrations of HA (5-50% percentage) reduces wild-type mineral produced (dose response and columns 5-8).

[0218] Example 4: Unexpected increase in mineralization with bioactive glasses This example describes the results obtained when bioactive glass was included in the compositions / scaffolds described herein. Again, testing was performed using the mineralization assay described in Example 2. The table below summarizes the unexpected improvement in mineralization observed when bioactive glass (BA) was included. The results are summarized in Figure 4. The first five columns show the effect of varying HA content from 0 to 50% on a mineralization rate of 100% to 0%. The hypomineralization of the scaffolds in the presence of sclerostin and O20221-1 can be restored by the addition of non-encapsulated bioactive glass (BA) (columns 6 and 7 compared to columns 2 and 3).

[0219] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, those skilled in the art will recognize that certain changes and modifications can be practiced within the scope of the appended claims. In addition, each reference provided herein is incorporated by reference in its entirety to the same extent as if each reference was individually incorporated by reference.

Claims

1. a) a scaffold comprising hydroxyapatite and tricalcium phosphate in a ratio of 0 / 100 to 15 / 85, collagen, and bioactive glass, the bioactive glass being uniformly distributed both in the interior and on the surface of the scaffold; b) Formula I: 【Chemistry 1】 [In the formula, X is CR 3b and N, where N is optionally oxidized to the corresponding N-oxide; Y is CR 3c and N, where N is optionally oxidized to the corresponding N-oxide; Z is CR 3d and N, where N is optionally oxidized to the corresponding N-oxide; with the proviso that at least one of X, Y and Z is N or the corresponding N-oxide; A is, 【Chemistry 2】 and R N is selected from the group consisting of heterocyclyl and heteroaryl; The heterocyclyl moieties are selected from monocyclic, fused bicyclic, and bridged bicyclic, the monocyclic heterocyclyls containing 4 to 7 ring members, the fused bicyclic and bridged bicyclic heterocyclyls containing 7 to 10 ring members, each heterocyclyl moiety having 1 to 3 heteroatoms as ring members selected from N, O, and S, each heterocyclyl moiety containing at least one nitrogen atom as a ring member, and 1 to 3 R 6 is optionally substituted with a moiety, The heteroaryl moiety contains 5 to 10 ring members, at least one ring member is a nitrogen atom, and 1 to 3 R 6 is optionally substituted with a moiety, Each R 2 , R 3b , R 3c and R 3d is H, halogen, C 16 Alkyl, C 16 Haloalkyl, C 26 Alkenyl, C 26 Alkynyl, C 16 Alkoxy, C 16 Haloalkoxy, C 16 AlkylOH, O-C 16 AlkylOH, C 3~6 Cycloalkyl-C 1~4 independently selected from the group consisting of alkoxy, and -OH; R 6 is -OH, C 1~3 Alkyl, C 13 AlkylOH, —O—C 1~3 Alkyl, C 3~4 Heteroalkyl, C 1~3 Haloalkyl, —O—C 1~3 or a salt, hydrate, prodrug, or isomer thereof; A sterile composition for bone formation, which is sterilized and packaged.

2. A composition for bone formation comprising a scaffold, the scaffold being a scaffold of hydroxyapatite (HA) and tricalcium phosphate (TCP) in a ratio of 0 / 100 to 15 / 85, collagen, and bioactive glass, the bioactive glass being uniformly dispersed both inside and on the surface of the scaffold, and the composition being sterilized and packaged.

3. The composition of claim 1 or 2, wherein the scaffold is in the form of granules, strips, blocks, spheres, putty, or liquid cement.

4. 3. The composition of claim 1 or 2, wherein the hydroxyapatite and the tricalcium phosphate are in a ratio of about 0 / 100, 5 / 95 or 10 / 90.

5. The composition of claim 1 or 2, wherein the bioactive glass has a particle size of about 50 microns to about 500 microns.

6. The composition of claim 1 or 2, wherein the bioactive glass has a particle size of about 90 microns to about 250 microns.

7. The composition of claim 1 or 2, which is moldable.

8. 3. The composition of claim 1 or 2, which has been sterilized using a method selected from the group consisting of gamma radiation, E-beam radiation, UV radiation, steam, dry heat, plasma, and chemical sterilization (ether, ethanol, iodine, or PAA).

9. Formula Ia, Ib, Ic, or Id: 【Chemistry 3】 2. The composition of claim 1 having the formula:

10. R 2 H, halogen, C 16 Alkyl, C 16 Haloalkyl, C 16 Alkoxy, and C 16 The composition of claim 9 , wherein the alkyl group is selected from the group consisting of haloalkoxy.

11. R 2 But halogen, C 16 Alkyl, C 16 Haloalkyl, and C 16 The composition of claim 9, wherein the alkyl group is selected from the group consisting of alkoxy.

12. R 2 But, C 1~6 Alkyl or C 16 The composition of claim 9 which is a haloalkyl.

13. R 2 CH 3 Or CF 3 10. The composition of claim 9, wherein

14. R 2 CH 3 10. The composition of claim 9, wherein

15. R 2 is CF 3 10. The composition of claim 9, wherein

16. R N The composition of claim 1 , wherein is heterocyclyl or heteroaryl.

17. R N The composition of claim 16, wherein is monocyclic heterocyclyl.

18. R N but, 【Chemistry 4】 18. The composition of claim 17, wherein

19. 【Chemical 5】 The composition of claim 17, selected from the group consisting of: or a salt, hydrate or prodrug thereof.

20. The composition of any one of claims 1 to 19, further comprising an additional bone forming agent.

21. 21. The composition of claim 20, wherein the bone forming agent is selected from the group consisting of P15, BMP2, BMP7, BMP4, PTH, anti-sclerostin antibodies, anti-sclerostin and anti-resorptive agents.

22. 22. A method of promoting bone formation in a subject in need thereof, comprising locally administering to said subject an effective amount of a composition according to any one of claims 1 to 21, thereby promoting bone formation in said subject.

23. 23. The method of claim 22, wherein the bone formation is promoted at a surgical site related to an injury or localized condition.

24. 24. The method of claim 23, wherein the bone formation is promoted at a surgical site selected from the group consisting of fractures and weakened bones.

25. 24. The method of claim 23, wherein the subject is in need of spinal fusion surgery, arthrodesis surgery, or an orthopedic or periodontal synthetic bone graft or implant.

26. 23. The method of claim 22, wherein the subject has a low bone mass / density condition, a fracture, or periodontal disease.

27. 27. The method of claim 26, wherein the low bone mass condition is selected from osteoporosis, osteopenia, osteogenesis imperfecta (OI), osteoporosis pseudoglioma syndrome (OPPG), and secondary low bone conditions.

28. 28. The method of claim 27, wherein the low bone mass condition is selected from the group consisting of osteoporosis, osteopenia, and osteoporosis pseudoglioma syndrome (OPPG).

29. 23. The method of claim 22, further comprising administering to the subject an additional osteoconductive matrix component.

30. 30. The method of claim 29, wherein the additional osteoconductive matrix component is selected from the group consisting of bone allograft, bone autograft, and periodontal ligament cells.

31. 30. The method of claim 29, wherein the additional osteoconductive matrix component is selected from the group consisting of calcium salts, calcium sulfate, calcium phosphate, calcium phosphate cement, hydroxyapatite, coral-based hydroxyapatite (HA), dicalcium phosphate, tricalcium phosphate (TCP), calcium carbonate, collagen, plaster of Paris, phosphophoryn, borosilicate, biocompatible ceramics, calcium phosphate ceramics, demineralized bone matrix, biphasic calcium phosphate, biocomposite, tantalum, titanium, polytetrafluoroethylene, sulfates, hydrogels, and combinations thereof.

32. 23. The method of claim 22, wherein the composition is administered continuously or in combination with an anti-resorptive agent.

33. 33. The method of claim 32, wherein the composition is administered topically to a subject being treated with the anti-resorptive agent or a subject who has previously been treated with the anti-resorptive agent.

34. 33. The method of claim 32, wherein the antiresorptive agent is selected from the group consisting of denosumab, Prolia, RankL inhibitors, bisphosphonates, selective estrogen receptor modulators (SERMs), calcitonin, calcitonin analogs, vitamin D, vitamin D analogs, and cathepsin K inhibitors.

35. A method for treating bone loss in a subject in need of such treatment, comprising administering to the subject a therapeutically effective composition of claim 1 either sequentially or in combination with an anti-resorptive agent, thereby treating bone loss in the subject.

Citation Information

Patent Citations

  • Bioactive bone graft substitute

    JP2009542347A

  • Bone repair composition and kit

    US20200197571A1

  • Pyrrolo - dipyridine compounds

    WO2020037004A1

Cited By

  • Artificial bone material and method for manufacturing the same

    JP7901937B1

  • Use of compositions in the manufacture of bone repair materials

    JP7903904B1